TY  - JOUR
AU  - Dajak, Marijana
AU  - Ignjatović, Svetlana
AU  - Stojimirović, Biljana
AU  - Gajić, Snežana
AU  - Majkić-Singh, Nada
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1400
PB  - Elsevier Science BV, Amsterdam
T2  - Clinica Chimica Acta
T1  - Urinary beta-trace protein as a tubular marker of renal dysfunction in patients with chronic kidney disease
VL  - 411
IS  - 15-16
SP  - 1154
EP  - 1155
DO  - 10.1016/j.cca.2010.04.013
ER  - 

@article{
author = "Dajak, Marijana and Ignjatović, Svetlana and Stojimirović, Biljana and Gajić, Snežana and Majkić-Singh, Nada",
year = "2010",
publisher = "Elsevier Science BV, Amsterdam",
journal = "Clinica Chimica Acta",
title = "Urinary beta-trace protein as a tubular marker of renal dysfunction in patients with chronic kidney disease",
volume = "411",
number = "15-16",
pages = "1154-1155",
doi = "10.1016/j.cca.2010.04.013"
}

Dajak, M., Ignjatović, S., Stojimirović, B., Gajić, S.,& Majkić-Singh, N.. (2010). Urinary beta-trace protein as a tubular marker of renal dysfunction in patients with chronic kidney disease. in Clinica Chimica Acta
Elsevier Science BV, Amsterdam., 411(15-16), 1154-1155.
https://doi.org/10.1016/j.cca.2010.04.013

Dajak M, Ignjatović S, Stojimirović B, Gajić S, Majkić-Singh N. Urinary beta-trace protein as a tubular marker of renal dysfunction in patients with chronic kidney disease. in Clinica Chimica Acta. 2010;411(15-16):1154-1155.
doi:10.1016/j.cca.2010.04.013 .

Dajak, Marijana, Ignjatović, Svetlana, Stojimirović, Biljana, Gajić, Snežana, Majkić-Singh, Nada, "Urinary beta-trace protein as a tubular marker of renal dysfunction in patients with chronic kidney disease" in Clinica Chimica Acta, 411, no. 15-16 (2010):1154-1155,
https://doi.org/10.1016/j.cca.2010.04.013 . .

TY  - JOUR
AU  - Marković, Mirjana
AU  - Ignjatović, Svetlana
AU  - Dajak, Marijana
AU  - Majkić-Singh, Nada
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1412
AB  - Background: Placental growth factor (PlGF) belongs to the vascular endothelial growth factor family and seems to be an independent biomarker for plaque disruption, ischemia, and thrombosis. Plasma PlGF is rapidly produced in infarcted myocardial tissue during the acute phase of myocardial infarction. In this study, the relevance of PIGF was analyzed at the admission of patients with acute coronary syndrome (ACS) without ST elevation for the prognosis of fatal outcome after 30 days. Methods: We collected blood samples from 102 ACS patients admitted to the coronary unit with manifesting acute chest pain within the previous 12 hours and measured the levels of PIGF, high-sensitivity C-reactive protein (hsCRP), and cardiac markers: troponin T (cTnT), B-type natriuretic peptide, creatine kinase-MB (CKMB) and CK activity. Results: PlGF, troponin T, and hsCRP levels were significantly higher in non-survivors than in survivors. ROC analysis showed that PIGF had the highest area under ROC curve (AUC, 0.713), but it was not significantly different from AUCs for cTnT and hsCRP. Higher values of PlGF (>13.2 ng/L) pointed towards a higher risk of fatal outcome (HR 2.28; 95 % CI 1.21-4.76; P=0.0125). The multivariable proportional hazards analysis, which had involved other statistically significant markers of relative risk (age and gender), showed that PlGF was an independent prognostic marker (adjusted HR 2.14; 95 % CI 1.08-4.22). Conclusions: These results confirmed that PlGF is an independent biomarker of short-term adverse outcome in patients with ACS without ST elevation and that plaque instability, represented by PlGF elevation, has an important role in the pathogenesis of future coronary events. (Clin. Lab. 2010;56:215-222)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome
VL  - 56
IS  - 5-6
SP  - 215
EP  - 222
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1412
ER  - 

@article{
author = "Marković, Mirjana and Ignjatović, Svetlana and Dajak, Marijana and Majkić-Singh, Nada",
year = "2010",
abstract = "Background: Placental growth factor (PlGF) belongs to the vascular endothelial growth factor family and seems to be an independent biomarker for plaque disruption, ischemia, and thrombosis. Plasma PlGF is rapidly produced in infarcted myocardial tissue during the acute phase of myocardial infarction. In this study, the relevance of PIGF was analyzed at the admission of patients with acute coronary syndrome (ACS) without ST elevation for the prognosis of fatal outcome after 30 days. Methods: We collected blood samples from 102 ACS patients admitted to the coronary unit with manifesting acute chest pain within the previous 12 hours and measured the levels of PIGF, high-sensitivity C-reactive protein (hsCRP), and cardiac markers: troponin T (cTnT), B-type natriuretic peptide, creatine kinase-MB (CKMB) and CK activity. Results: PlGF, troponin T, and hsCRP levels were significantly higher in non-survivors than in survivors. ROC analysis showed that PIGF had the highest area under ROC curve (AUC, 0.713), but it was not significantly different from AUCs for cTnT and hsCRP. Higher values of PlGF (>13.2 ng/L) pointed towards a higher risk of fatal outcome (HR 2.28; 95 % CI 1.21-4.76; P=0.0125). The multivariable proportional hazards analysis, which had involved other statistically significant markers of relative risk (age and gender), showed that PlGF was an independent prognostic marker (adjusted HR 2.14; 95 % CI 1.08-4.22). Conclusions: These results confirmed that PlGF is an independent biomarker of short-term adverse outcome in patients with ACS without ST elevation and that plaque instability, represented by PlGF elevation, has an important role in the pathogenesis of future coronary events. (Clin. Lab. 2010;56:215-222)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome",
volume = "56",
number = "5-6",
pages = "215-222",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1412"
}

Marković, M., Ignjatović, S., Dajak, M.,& Majkić-Singh, N.. (2010). Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 56(5-6), 215-222.
https://hdl.handle.net/21.15107/rcub_farfar_1412

Marković M, Ignjatović S, Dajak M, Majkić-Singh N. Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome. in Clinical Laboratory. 2010;56(5-6):215-222.
https://hdl.handle.net/21.15107/rcub_farfar_1412 .

Marković, Mirjana, Ignjatović, Svetlana, Dajak, Marijana, Majkić-Singh, Nada, "Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome" in Clinical Laboratory, 56, no. 5-6 (2010):215-222,
https://hdl.handle.net/21.15107/rcub_farfar_1412 .

TY  - JOUR
AU  - Marković, Mirjana
AU  - Ignjatović, Svetlana
AU  - Dajak, Marijana
AU  - Majkić-Singh, Nada
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1362
AB  - Objectives: The relevance of placental growth factor was analyzed at the admission of patients with acute coronary syndrome (ACS) without ST elevation in prognosis of fatal outcome after 30 days. Methods: We collected blood samples from 102 ACS patients admitted to the coronary unit with acute chest pain manifesting within the last 12 hours. Results: In all 102 admitted patients, higher values of placental growth factor (PLGF; >13.2 ng/L, average value) indicated a higher risk of fatal outcome (hazard ratio [HR] 2.28, 95% confidence interval [CI] 1.21-4.76, P = 0.0125). PLGF is an important independent prognostic marker (adjusted HR 2.35, 95% CI 1.98-4.61, P = 0.1338), and this was shown in a multiparameter model, which involved other statistically important markers of relative risk (age >65, gender, and estimated glomerular filtration rate [eGFR]). Conclusion: PLGF levels measured at 12 hours of symptom onset and 30 days later may independently predict fatal outcome in patients with ACS without ST elevation.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
T1  - Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction
VL  - 103
IS  - 10
SP  - 982
EP  - 987
DO  - 10.1097/SMJ.0b013e3181eda4ef
ER  - 

@article{
author = "Marković, Mirjana and Ignjatović, Svetlana and Dajak, Marijana and Majkić-Singh, Nada",
year = "2010",
abstract = "Objectives: The relevance of placental growth factor was analyzed at the admission of patients with acute coronary syndrome (ACS) without ST elevation in prognosis of fatal outcome after 30 days. Methods: We collected blood samples from 102 ACS patients admitted to the coronary unit with acute chest pain manifesting within the last 12 hours. Results: In all 102 admitted patients, higher values of placental growth factor (PLGF; >13.2 ng/L, average value) indicated a higher risk of fatal outcome (hazard ratio [HR] 2.28, 95% confidence interval [CI] 1.21-4.76, P = 0.0125). PLGF is an important independent prognostic marker (adjusted HR 2.35, 95% CI 1.98-4.61, P = 0.1338), and this was shown in a multiparameter model, which involved other statistically important markers of relative risk (age >65, gender, and estimated glomerular filtration rate [eGFR]). Conclusion: PLGF levels measured at 12 hours of symptom onset and 30 days later may independently predict fatal outcome in patients with ACS without ST elevation.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy",
title = "Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction",
volume = "103",
number = "10",
pages = "982-987",
doi = "10.1097/SMJ.0b013e3181eda4ef"
}

Marković, M., Ignjatović, S., Dajak, M.,& Majkić-Singh, N.. (2010). Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction. in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Lippincott Williams & Wilkins, Philadelphia., 103(10), 982-987.
https://doi.org/10.1097/SMJ.0b013e3181eda4ef

Marković M, Ignjatović S, Dajak M, Majkić-Singh N. Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction. in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2010;103(10):982-987.
doi:10.1097/SMJ.0b013e3181eda4ef .

Marković, Mirjana, Ignjatović, Svetlana, Dajak, Marijana, Majkić-Singh, Nada, "Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction" in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 103, no. 10 (2010):982-987,
https://doi.org/10.1097/SMJ.0b013e3181eda4ef . .

TY  - JOUR
AU  - Beletić, Anđelo
AU  - Đorđević, Valentina
AU  - Dudvarski-Ilić, Aleksandra
AU  - Obradović, Ivana
AU  - Mirković, Duško
AU  - Ilić, Mirka
AU  - Radojković, Dragica
AU  - Majkić-Singh, Nada
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1163
AB  - Alpha-1-antitrypsin deficiency is a potentially lethal genetic disorder, which has pulmonary and liver manifestations. The standardized biochemical and molecular diagnostic protocol for detection of clinically relevant alleles is needed. The paper summarizes current concepts about AATD, describes the potentials of isoelectric focusing and PCR amplification-reverse allele specific oligonucleotide hybridization assay in the detection of affected individuals and shortly presents our experiences in the evaluation of AATD. We conclude that the systematic clinical laboratory approach to AATD might be based on the combination of mentioned methods, coordinated by alpha-1-antritrypsin quantification. Additionally, its complete medical implementation is achieved through teamwork between clinical chemists, molecular biologists and clinicians.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Isoelectrofocusing and PCR Amplification-Reverse Hybridization Assay in Evaluation of Alpha-1-Antitrypsin Deficiency
VL  - 28
IS  - 4
SP  - 241
EP  - 247
DO  - 10.2478/v10011-009-0023-x
ER  - 

@article{
author = "Beletić, Anđelo and Đorđević, Valentina and Dudvarski-Ilić, Aleksandra and Obradović, Ivana and Mirković, Duško and Ilić, Mirka and Radojković, Dragica and Majkić-Singh, Nada",
year = "2009",
abstract = "Alpha-1-antitrypsin deficiency is a potentially lethal genetic disorder, which has pulmonary and liver manifestations. The standardized biochemical and molecular diagnostic protocol for detection of clinically relevant alleles is needed. The paper summarizes current concepts about AATD, describes the potentials of isoelectric focusing and PCR amplification-reverse allele specific oligonucleotide hybridization assay in the detection of affected individuals and shortly presents our experiences in the evaluation of AATD. We conclude that the systematic clinical laboratory approach to AATD might be based on the combination of mentioned methods, coordinated by alpha-1-antritrypsin quantification. Additionally, its complete medical implementation is achieved through teamwork between clinical chemists, molecular biologists and clinicians.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Isoelectrofocusing and PCR Amplification-Reverse Hybridization Assay in Evaluation of Alpha-1-Antitrypsin Deficiency",
volume = "28",
number = "4",
pages = "241-247",
doi = "10.2478/v10011-009-0023-x"
}

Beletić, A., Đorđević, V., Dudvarski-Ilić, A., Obradović, I., Mirković, D., Ilić, M., Radojković, D.,& Majkić-Singh, N.. (2009). Isoelectrofocusing and PCR Amplification-Reverse Hybridization Assay in Evaluation of Alpha-1-Antitrypsin Deficiency. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 28(4), 241-247.
https://doi.org/10.2478/v10011-009-0023-x

Beletić A, Đorđević V, Dudvarski-Ilić A, Obradović I, Mirković D, Ilić M, Radojković D, Majkić-Singh N. Isoelectrofocusing and PCR Amplification-Reverse Hybridization Assay in Evaluation of Alpha-1-Antitrypsin Deficiency. in Journal of Medical Biochemistry. 2009;28(4):241-247.
doi:10.2478/v10011-009-0023-x .

Beletić, Anđelo, Đorđević, Valentina, Dudvarski-Ilić, Aleksandra, Obradović, Ivana, Mirković, Duško, Ilić, Mirka, Radojković, Dragica, Majkić-Singh, Nada, "Isoelectrofocusing and PCR Amplification-Reverse Hybridization Assay in Evaluation of Alpha-1-Antitrypsin Deficiency" in Journal of Medical Biochemistry, 28, no. 4 (2009):241-247,
https://doi.org/10.2478/v10011-009-0023-x . .

TY  - JOUR
AU  - Milinković, Neda
AU  - Majkić-Singh, Nada
AU  - Mirković, Duško
AU  - Beletić, Anđelo
AU  - Pejanović, Svetlana D.
AU  - Vujanić, Svetlana T.
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1189
AB  - Deficient serum 25-hydroxyvitamin D [25(OH)D] may contribute to the impaired bone turnover of end stage renal disease patients. In 112 hemodialysed patients we analysed the relation between 25(OH)D and bone alkaline phosphatase (BALP), beta-CrossLaps (beta-CTx) and iPTH. We analysed parameters according to the manufacturers' instructions. We found potentially significant vitamin D deficiency: 71% of patients had 25(OH)D levels below 50 nmol/L. In patients with iPTH below 150 pg/mL (n = 57), we observed significantly low 25(OH) (p lt 0.01). In addition, patients with iPTH above 300 pg/mL had higher BALP levels (p lt 0.05). There were negative correlations between serum 25(OH)D and both BALP and iPTH (r = -0.225, p lt 0.05 and r = -0.331, p lt 0.05). Beta-CTx levels were significantly higher in patients who did not receive vitamin D supplementation (p lt 0.01). In addition, reduced BALP and iPTH levels indicate decreased bone turnover. Recorded data could signify that vitamin D deficiency may contribute to the impaired bone metabolism of hemodialysis patients. (Clin. Lab. 2009;55:333-339)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - Relation Between 25(OH)-Vitamin D Deficiency and Markers of Bone Formation and Resorption in Haemodialysis Patients
VL  - 55
IS  - 9-10
SP  - 333
EP  - 339
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1189
ER  - 

@article{
author = "Milinković, Neda and Majkić-Singh, Nada and Mirković, Duško and Beletić, Anđelo and Pejanović, Svetlana D. and Vujanić, Svetlana T.",
year = "2009",
abstract = "Deficient serum 25-hydroxyvitamin D [25(OH)D] may contribute to the impaired bone turnover of end stage renal disease patients. In 112 hemodialysed patients we analysed the relation between 25(OH)D and bone alkaline phosphatase (BALP), beta-CrossLaps (beta-CTx) and iPTH. We analysed parameters according to the manufacturers' instructions. We found potentially significant vitamin D deficiency: 71% of patients had 25(OH)D levels below 50 nmol/L. In patients with iPTH below 150 pg/mL (n = 57), we observed significantly low 25(OH) (p lt 0.01). In addition, patients with iPTH above 300 pg/mL had higher BALP levels (p lt 0.05). There were negative correlations between serum 25(OH)D and both BALP and iPTH (r = -0.225, p lt 0.05 and r = -0.331, p lt 0.05). Beta-CTx levels were significantly higher in patients who did not receive vitamin D supplementation (p lt 0.01). In addition, reduced BALP and iPTH levels indicate decreased bone turnover. Recorded data could signify that vitamin D deficiency may contribute to the impaired bone metabolism of hemodialysis patients. (Clin. Lab. 2009;55:333-339)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "Relation Between 25(OH)-Vitamin D Deficiency and Markers of Bone Formation and Resorption in Haemodialysis Patients",
volume = "55",
number = "9-10",
pages = "333-339",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1189"
}

Milinković, N., Majkić-Singh, N., Mirković, D., Beletić, A., Pejanović, S. D.,& Vujanić, S. T.. (2009). Relation Between 25(OH)-Vitamin D Deficiency and Markers of Bone Formation and Resorption in Haemodialysis Patients. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 55(9-10), 333-339.
https://hdl.handle.net/21.15107/rcub_farfar_1189

Milinković N, Majkić-Singh N, Mirković D, Beletić A, Pejanović SD, Vujanić ST. Relation Between 25(OH)-Vitamin D Deficiency and Markers of Bone Formation and Resorption in Haemodialysis Patients. in Clinical Laboratory. 2009;55(9-10):333-339.
https://hdl.handle.net/21.15107/rcub_farfar_1189 .

Milinković, Neda, Majkić-Singh, Nada, Mirković, Duško, Beletić, Anđelo, Pejanović, Svetlana D., Vujanić, Svetlana T., "Relation Between 25(OH)-Vitamin D Deficiency and Markers of Bone Formation and Resorption in Haemodialysis Patients" in Clinical Laboratory, 55, no. 9-10 (2009):333-339,
https://hdl.handle.net/21.15107/rcub_farfar_1189 .

TY  - JOUR
AU  - Beletić, Anđelo
AU  - Mirković, Duško
AU  - Antonijević, Nebojša
AU  - Đorđević, Valentina
AU  - Sango, Violeta
AU  - Jakovljević, Branko
AU  - Perunicić, Jovan
AU  - Ilić, Mirka
AU  - Vasiljević, Zorana
AU  - Majkić-Singh, Nada
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1168
AB  - Hyperhomocysteinemia is considered an independent risk factor for premature cardiovascular disease. Mutation MTHFR C677T reduces the activity of methylenetetra-hydrofolatereductase and may cause hyperhomocysteinemia. Incidence of hyperhomocysteinemia (homocysteine above 12 mu mol/L), homocysteine level, and distribution of MTHFR C677T genotypes (C/C, C/T and T/T) are T/T) are compared between young patients with acute myocardial infarction and healthy persons, matched by age. Study involved 86 patients younger than 45 years (77 men and 9 women) and 35 controls. Homocysteine was measured by an HPLC method and the MTHFR C677T genotype determined using PCR amplification and digestion with Hinf I. Statistical analyses included chisquare and Mann-Whitney U tests. Hyperhomocysteinemia was present in 32.6% patients and 14.3% controls, revealing a significant difference (P = 0.038). Median homocysteine levels in patients (10.4 mu mol/L) and controls (9.6 mu mol/L) were significantly different (P=0.035). Among patients, 50.0% had C/C, 41.9% C/T and 8.1% T/T genotype, and the genotype had no influence on hyperhomocysteinemia incidence and homocysteine level. Genotype distribution in patients was not significantly different from the observed in controls. The conclusion is that young patients with acute myocardial infarction have higher incidence of hyperhomocysteinemia and higher homocysteine levels than healthy young adults, while there is no significant difference in the distribution of MTHFR C677T genotypes.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction
VL  - 28
IS  - 1
SP  - 41
EP  - 45
DO  - 10.2478/v10011-008-0029-9
ER  - 

@article{
author = "Beletić, Anđelo and Mirković, Duško and Antonijević, Nebojša and Đorđević, Valentina and Sango, Violeta and Jakovljević, Branko and Perunicić, Jovan and Ilić, Mirka and Vasiljević, Zorana and Majkić-Singh, Nada",
year = "2009",
abstract = "Hyperhomocysteinemia is considered an independent risk factor for premature cardiovascular disease. Mutation MTHFR C677T reduces the activity of methylenetetra-hydrofolatereductase and may cause hyperhomocysteinemia. Incidence of hyperhomocysteinemia (homocysteine above 12 mu mol/L), homocysteine level, and distribution of MTHFR C677T genotypes (C/C, C/T and T/T) are T/T) are compared between young patients with acute myocardial infarction and healthy persons, matched by age. Study involved 86 patients younger than 45 years (77 men and 9 women) and 35 controls. Homocysteine was measured by an HPLC method and the MTHFR C677T genotype determined using PCR amplification and digestion with Hinf I. Statistical analyses included chisquare and Mann-Whitney U tests. Hyperhomocysteinemia was present in 32.6% patients and 14.3% controls, revealing a significant difference (P = 0.038). Median homocysteine levels in patients (10.4 mu mol/L) and controls (9.6 mu mol/L) were significantly different (P=0.035). Among patients, 50.0% had C/C, 41.9% C/T and 8.1% T/T genotype, and the genotype had no influence on hyperhomocysteinemia incidence and homocysteine level. Genotype distribution in patients was not significantly different from the observed in controls. The conclusion is that young patients with acute myocardial infarction have higher incidence of hyperhomocysteinemia and higher homocysteine levels than healthy young adults, while there is no significant difference in the distribution of MTHFR C677T genotypes.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction",
volume = "28",
number = "1",
pages = "41-45",
doi = "10.2478/v10011-008-0029-9"
}

Beletić, A., Mirković, D., Antonijević, N., Đorđević, V., Sango, V., Jakovljević, B., Perunicić, J., Ilić, M., Vasiljević, Z.,& Majkić-Singh, N.. (2009). Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 28(1), 41-45.
https://doi.org/10.2478/v10011-008-0029-9

Beletić A, Mirković D, Antonijević N, Đorđević V, Sango V, Jakovljević B, Perunicić J, Ilić M, Vasiljević Z, Majkić-Singh N. Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction. in Journal of Medical Biochemistry. 2009;28(1):41-45.
doi:10.2478/v10011-008-0029-9 .

Beletić, Anđelo, Mirković, Duško, Antonijević, Nebojša, Đorđević, Valentina, Sango, Violeta, Jakovljević, Branko, Perunicić, Jovan, Ilić, Mirka, Vasiljević, Zorana, Majkić-Singh, Nada, "Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction" in Journal of Medical Biochemistry, 28, no. 1 (2009):41-45,
https://doi.org/10.2478/v10011-008-0029-9 . .

TY  - JOUR
AU  - Becarević, Mirjana
AU  - Mirković, Duško
AU  - Majkić-Singh, Nada
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1161
AB  - The thrombotic tendency in anti phospholipid syndrome (APS) shares several pathways with atherosclerosis. Atherothrombosis (atherosclerosis superimposed with thromboses) is influenced by nonmodifiable and some modifiable risk factors (smoking, obesity, physical inactivity, alcohol abuse, hyperhomocysteinemia). Therefore, we investigated the association among clinical and serological features of patients with primary APS and potentially modifiable risk factors for the development of atherothrombosis. Also, we compared the analyzed parameters with those in control subjects. Homo cysteine concentrations were detected by HPLC (high performance liquid chromatography), while antiphospholipid antibodies were detected by ELISA. Smokers had elevated levels of homocysteine (chi(2) = 6.22, p  lt  0.05). Independently of patients' age, the association between increased levels of homocysteine and history of myocardial infarctions was found (chi(2) = 4.61, p  lt  0.05). Hyperhomocysteinemia and smoking are the most important modifiable risk factors for atherothrombosis in primary APS.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Hyperhomocysteinemia and smoking in primary antiphospholipid syndrome
VL  - 28
IS  - 3
SP  - 172
EP  - 175
DO  - 10.2478/v10011-009-0019-6
ER  - 

@article{
author = "Becarević, Mirjana and Mirković, Duško and Majkić-Singh, Nada",
year = "2009",
abstract = "The thrombotic tendency in anti phospholipid syndrome (APS) shares several pathways with atherosclerosis. Atherothrombosis (atherosclerosis superimposed with thromboses) is influenced by nonmodifiable and some modifiable risk factors (smoking, obesity, physical inactivity, alcohol abuse, hyperhomocysteinemia). Therefore, we investigated the association among clinical and serological features of patients with primary APS and potentially modifiable risk factors for the development of atherothrombosis. Also, we compared the analyzed parameters with those in control subjects. Homo cysteine concentrations were detected by HPLC (high performance liquid chromatography), while antiphospholipid antibodies were detected by ELISA. Smokers had elevated levels of homocysteine (chi(2) = 6.22, p  lt  0.05). Independently of patients' age, the association between increased levels of homocysteine and history of myocardial infarctions was found (chi(2) = 4.61, p  lt  0.05). Hyperhomocysteinemia and smoking are the most important modifiable risk factors for atherothrombosis in primary APS.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Hyperhomocysteinemia and smoking in primary antiphospholipid syndrome",
volume = "28",
number = "3",
pages = "172-175",
doi = "10.2478/v10011-009-0019-6"
}

Becarević, M., Mirković, D.,& Majkić-Singh, N.. (2009). Hyperhomocysteinemia and smoking in primary antiphospholipid syndrome. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 28(3), 172-175.
https://doi.org/10.2478/v10011-009-0019-6

Becarević M, Mirković D, Majkić-Singh N. Hyperhomocysteinemia and smoking in primary antiphospholipid syndrome. in Journal of Medical Biochemistry. 2009;28(3):172-175.
doi:10.2478/v10011-009-0019-6 .

Becarević, Mirjana, Mirković, Duško, Majkić-Singh, Nada, "Hyperhomocysteinemia and smoking in primary antiphospholipid syndrome" in Journal of Medical Biochemistry, 28, no. 3 (2009):172-175,
https://doi.org/10.2478/v10011-009-0019-6 . .

TY  - JOUR
AU  - Marković, Mirjana
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Dajak, Marijana
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1165
AB  - Background: Markers of plaque instability are considered as predictors of future events in patients with non ST-elevation myocardial infarction (NSTEMI) in acute coronary syndrome (ACS). The aim of this was to determine the role of placental growth factor (PIGF) as a possible: predictor of future coronary events such as non-fatal myocardial infarction or cardiac death measured at the admission and 30 days, after discharge. Methods: We prospectively collected data from 102 patients admitted to the emergency department (ED) for ACS with chest pain at rest within the preceding 12 hours who were evaluated by risk factors and electrocardiogram changes (ECG). Results: The time course of PIGF levels. determined on 102 patients showed a mean. value 13.21 ng/L and standard deviation 8.76 ng/L but in the sample of the 53 patients who survived after 30 days, these values decreased to 10.48 ng/L and 5.45 ng/L, respectively, Conclusions: Results of this study indicate a clinically useful role of PIGF in the detection of ACS and NSTEMI patients who are at a higher risk for different cardiovascular disorders within 30 days of admission.
PB  - Amer Soc Clinical Pathology, Chicago
T2  - Labmedicine
T1  - Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation
VL  - 40
IS  - 11
SP  - 675
EP  - 678
DO  - 10.1309/LMK6X47RSYRCGCSB
ER  - 

@article{
author = "Marković, Mirjana and Ignjatović, Svetlana and Majkić-Singh, Nada and Dajak, Marijana",
year = "2009",
abstract = "Background: Markers of plaque instability are considered as predictors of future events in patients with non ST-elevation myocardial infarction (NSTEMI) in acute coronary syndrome (ACS). The aim of this was to determine the role of placental growth factor (PIGF) as a possible: predictor of future coronary events such as non-fatal myocardial infarction or cardiac death measured at the admission and 30 days, after discharge. Methods: We prospectively collected data from 102 patients admitted to the emergency department (ED) for ACS with chest pain at rest within the preceding 12 hours who were evaluated by risk factors and electrocardiogram changes (ECG). Results: The time course of PIGF levels. determined on 102 patients showed a mean. value 13.21 ng/L and standard deviation 8.76 ng/L but in the sample of the 53 patients who survived after 30 days, these values decreased to 10.48 ng/L and 5.45 ng/L, respectively, Conclusions: Results of this study indicate a clinically useful role of PIGF in the detection of ACS and NSTEMI patients who are at a higher risk for different cardiovascular disorders within 30 days of admission.",
publisher = "Amer Soc Clinical Pathology, Chicago",
journal = "Labmedicine",
title = "Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation",
volume = "40",
number = "11",
pages = "675-678",
doi = "10.1309/LMK6X47RSYRCGCSB"
}

Marković, M., Ignjatović, S., Majkić-Singh, N.,& Dajak, M.. (2009). Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation. in Labmedicine
Amer Soc Clinical Pathology, Chicago., 40(11), 675-678.
https://doi.org/10.1309/LMK6X47RSYRCGCSB

Marković M, Ignjatović S, Majkić-Singh N, Dajak M. Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation. in Labmedicine. 2009;40(11):675-678.
doi:10.1309/LMK6X47RSYRCGCSB .

Marković, Mirjana, Ignjatović, Svetlana, Majkić-Singh, Nada, Dajak, Marijana, "Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation" in Labmedicine, 40, no. 11 (2009):675-678,
https://doi.org/10.1309/LMK6X47RSYRCGCSB . .

TY  - JOUR
AU  - Jovičić, Snežana
AU  - Ignjatović, Svetlana
AU  - Dajak, Marijana
AU  - Kangrga, Ranka
AU  - Majkić-Singh, Nada
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1198
AB  - Background: High-sensitivity C-reactive protein (hsCRP) has been recognized as an independent marker of cardiovascular risk. Since atherosclerosis is a multifactorial disease, the aim of this study was to determine association between hsCRP and other markers of inflammation and dyslipidemia. Materials and Methods: In 242 healthy volunteers, total cholesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), nonHDL-C, triglycerides (TG) and hsCRP were measured using Olympus AU2700. Apolipoprotein A-1 (apoA1), apolipoprotein B (apo B), lipoprotein (a) (Lp(a)), haptoglobin, alpha(1)-acid glycoprotein (A1AGP), C3 and C4 complement components were determined on Architect c8000, and serum amyloid A (SAA) and fibrinogen on BN II nephelometer and ACL 7000, respectively. Results: Significant (P  lt  0.05) partial Pearson's correlation coefficients were found between hsCRP and TC (r = 0.172), nonHDL-C (r = 0.182), LDL-C (r = 0.154), apoB (r = 0.167), fibrinogen (r = 0.411), SAA (r = 0.493), A1AGP (r = 0.462), haptoglobin (r = 0.310), C3 (r = 0.349) and C4 (r = 0.371). In multiple regression analysis, BMI, SAA, A1AGP, fibrinogen and nonHDL-C showed independent correlation with hsCRP. Multinomial logistic regression analysis demonstrated that BMI, nonHDL, fibrinogen and SAA were strong predictors of hsCRP concentration. Odds ratios for intermediate and high risk categories compared with the low risk category were 1.177 (1.033-1.341) and 1.289 (1.091-1.523), 1.515 (1.021-2.249) and 2.062 (1.246-3.411), 2.241 (1.268-3.959) and 7.123 (3.259-15.568), and 1.387 (1.179-1.632) and 1.691 (1.397-2.047), for BMI, nonHDL-C, fibrinogen and SAA, respectively. Conclusion: The prediction of risk for future cardiac events based on hsCRP concentration, which is the recommended parameter for improving cardiovascular risk stratification, might be complemented with the information about BMI, nonHDL-C, fibrinogen and SAA. (Clin. Lab. 2009;55:411-419)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - Association of Lipid and Inflammatory Markers with C-Reactive Protein in Cardiovascular Risk Assessment for Primary Prevention
VL  - 55
IS  - 11-12
SP  - 411
EP  - 419
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1198
ER  - 

@article{
author = "Jovičić, Snežana and Ignjatović, Svetlana and Dajak, Marijana and Kangrga, Ranka and Majkić-Singh, Nada",
year = "2009",
abstract = "Background: High-sensitivity C-reactive protein (hsCRP) has been recognized as an independent marker of cardiovascular risk. Since atherosclerosis is a multifactorial disease, the aim of this study was to determine association between hsCRP and other markers of inflammation and dyslipidemia. Materials and Methods: In 242 healthy volunteers, total cholesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), nonHDL-C, triglycerides (TG) and hsCRP were measured using Olympus AU2700. Apolipoprotein A-1 (apoA1), apolipoprotein B (apo B), lipoprotein (a) (Lp(a)), haptoglobin, alpha(1)-acid glycoprotein (A1AGP), C3 and C4 complement components were determined on Architect c8000, and serum amyloid A (SAA) and fibrinogen on BN II nephelometer and ACL 7000, respectively. Results: Significant (P  lt  0.05) partial Pearson's correlation coefficients were found between hsCRP and TC (r = 0.172), nonHDL-C (r = 0.182), LDL-C (r = 0.154), apoB (r = 0.167), fibrinogen (r = 0.411), SAA (r = 0.493), A1AGP (r = 0.462), haptoglobin (r = 0.310), C3 (r = 0.349) and C4 (r = 0.371). In multiple regression analysis, BMI, SAA, A1AGP, fibrinogen and nonHDL-C showed independent correlation with hsCRP. Multinomial logistic regression analysis demonstrated that BMI, nonHDL, fibrinogen and SAA were strong predictors of hsCRP concentration. Odds ratios for intermediate and high risk categories compared with the low risk category were 1.177 (1.033-1.341) and 1.289 (1.091-1.523), 1.515 (1.021-2.249) and 2.062 (1.246-3.411), 2.241 (1.268-3.959) and 7.123 (3.259-15.568), and 1.387 (1.179-1.632) and 1.691 (1.397-2.047), for BMI, nonHDL-C, fibrinogen and SAA, respectively. Conclusion: The prediction of risk for future cardiac events based on hsCRP concentration, which is the recommended parameter for improving cardiovascular risk stratification, might be complemented with the information about BMI, nonHDL-C, fibrinogen and SAA. (Clin. Lab. 2009;55:411-419)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "Association of Lipid and Inflammatory Markers with C-Reactive Protein in Cardiovascular Risk Assessment for Primary Prevention",
volume = "55",
number = "11-12",
pages = "411-419",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1198"
}

Jovičić, S., Ignjatović, S., Dajak, M., Kangrga, R.,& Majkić-Singh, N.. (2009). Association of Lipid and Inflammatory Markers with C-Reactive Protein in Cardiovascular Risk Assessment for Primary Prevention. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 55(11-12), 411-419.
https://hdl.handle.net/21.15107/rcub_farfar_1198

Jovičić S, Ignjatović S, Dajak M, Kangrga R, Majkić-Singh N. Association of Lipid and Inflammatory Markers with C-Reactive Protein in Cardiovascular Risk Assessment for Primary Prevention. in Clinical Laboratory. 2009;55(11-12):411-419.
https://hdl.handle.net/21.15107/rcub_farfar_1198 .

Jovičić, Snežana, Ignjatović, Svetlana, Dajak, Marijana, Kangrga, Ranka, Majkić-Singh, Nada, "Association of Lipid and Inflammatory Markers with C-Reactive Protein in Cardiovascular Risk Assessment for Primary Prevention" in Clinical Laboratory, 55, no. 11-12 (2009):411-419,
https://hdl.handle.net/21.15107/rcub_farfar_1198 .

TY  - JOUR
AU  - Ninković, Milica
AU  - Selaković, Vesna
AU  - Đukić, Mirjana
AU  - Milosavljević, Petar
AU  - Vasiljević, Ivana
AU  - Jovanović, Marina
AU  - Maličević, Živorad
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1060
AB  - Aim: The mechanism of MDMA (3,4-methylenedioxymethamphetamine)-induced toxicity is believed to be, in part, due to enhanced oxidative stress. As MDMA is eliminated via the kidney, the aim. of this study was to investigate whether MDMA created conditions of oxidative stress within rat kidney. Methods: Adult male Wistar rats were divided into three groups, control treatment (water), acute MDMA administration (single oral dose: 5, 10, 20 or 40 mg/kg body weight) and subacute MDMA administration (5, 10, or 20 mg/kg body weight per day during 14 days). Animals were sacrificed 8 h after the single oral MDMA administration in the acute MDMA administration group and after the last MDMA administration in the subacute MDMA administration group. Rectal temperature measurements, oxidative stress status parameters and histological examinations were performed. Results: In all MDMA-administered rats, rectal temperature markedly increased peaking approximately 1 h after MDMA ingestion. Superoxide dismutase activity and thiobarbituric acid reactive substances increased after MDMA administration. Histological examinations of the kidney revealed dose-dependent disruption of tissue structure in subacute MDMA-administered rats. The latter was not observed in acute MDMA-administered rats.
PB  - Wiley, Hoboken
T2  - Nephrology
T1  - Oxidative stress in rat kidneys due to 3,4-methylenedioxymetamphetamine (ecstasy) toxicity
VL  - 13
IS  - 1
SP  - 33
EP  - 37
DO  - 10.1111/j.1440-1797.2007.00886.x
ER  - 

@article{
author = "Ninković, Milica and Selaković, Vesna and Đukić, Mirjana and Milosavljević, Petar and Vasiljević, Ivana and Jovanović, Marina and Maličević, Živorad",
year = "2008",
abstract = "Aim: The mechanism of MDMA (3,4-methylenedioxymethamphetamine)-induced toxicity is believed to be, in part, due to enhanced oxidative stress. As MDMA is eliminated via the kidney, the aim. of this study was to investigate whether MDMA created conditions of oxidative stress within rat kidney. Methods: Adult male Wistar rats were divided into three groups, control treatment (water), acute MDMA administration (single oral dose: 5, 10, 20 or 40 mg/kg body weight) and subacute MDMA administration (5, 10, or 20 mg/kg body weight per day during 14 days). Animals were sacrificed 8 h after the single oral MDMA administration in the acute MDMA administration group and after the last MDMA administration in the subacute MDMA administration group. Rectal temperature measurements, oxidative stress status parameters and histological examinations were performed. Results: In all MDMA-administered rats, rectal temperature markedly increased peaking approximately 1 h after MDMA ingestion. Superoxide dismutase activity and thiobarbituric acid reactive substances increased after MDMA administration. Histological examinations of the kidney revealed dose-dependent disruption of tissue structure in subacute MDMA-administered rats. The latter was not observed in acute MDMA-administered rats.",
publisher = "Wiley, Hoboken",
journal = "Nephrology",
title = "Oxidative stress in rat kidneys due to 3,4-methylenedioxymetamphetamine (ecstasy) toxicity",
volume = "13",
number = "1",
pages = "33-37",
doi = "10.1111/j.1440-1797.2007.00886.x"
}

Ninković, M., Selaković, V., Đukić, M., Milosavljević, P., Vasiljević, I., Jovanović, M.,& Maličević, Ž.. (2008). Oxidative stress in rat kidneys due to 3,4-methylenedioxymetamphetamine (ecstasy) toxicity. in Nephrology
Wiley, Hoboken., 13(1), 33-37.
https://doi.org/10.1111/j.1440-1797.2007.00886.x

Ninković M, Selaković V, Đukić M, Milosavljević P, Vasiljević I, Jovanović M, Maličević Ž. Oxidative stress in rat kidneys due to 3,4-methylenedioxymetamphetamine (ecstasy) toxicity. in Nephrology. 2008;13(1):33-37.
doi:10.1111/j.1440-1797.2007.00886.x .

Ninković, Milica, Selaković, Vesna, Đukić, Mirjana, Milosavljević, Petar, Vasiljević, Ivana, Jovanović, Marina, Maličević, Živorad, "Oxidative stress in rat kidneys due to 3,4-methylenedioxymetamphetamine (ecstasy) toxicity" in Nephrology, 13, no. 1 (2008):33-37,
https://doi.org/10.1111/j.1440-1797.2007.00886.x . .

TY  - JOUR
AU  - Đukić, Mirjana
AU  - Ninković, Milica
AU  - Jovanović, Marina
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1040
AB  - Elevated free radical production and/or insufficient antioxidative defense results in cellular oxidant stress responses. Sustained and/or intense oxidative insults can overcome cell defenses resulting in accumulated damage to macromolecules, leading to loss of cell function, membrane damage, and ultimately to cell death. Oxidative stress (OS) can result from conditions including excessive physical stress, exposure to environmental pollution and xenobiotics, and smoking. Oxidative stress, as a pathophysiological mechanism, has been linked to numerous pathologies, poisonings, and the ageing process. Reactive oxygen species and reactive nitrogen species, endogenously or exogenously produced, can readily attack all classes of macromolecules (proteins, DNA, unsaturated fatty acid). The disrupted oxidative-reductive milieu proceeds via lipid peroxidation, altered antioxidative enzyme activities and depletion of non-enzymatic endogenous antioxidants, several of which can de detected in the pre-symptomatic phase of many diseases. Therefore, they could represent markers of altered metabolic and physiological homeostasis. Accordingly, from the point of view of routine clinical-diagnostic practice, it would be valuable to routinely analyze OS status parameters to earlier recognize potential disease states and provide the basis for preventative advance treatment with appropriate medicines.
AB  - Povećano stvaranje slobodnih radikala i/ili nedovoljna antioksidativna zaštita dovodi do oksidativnog stre sa (OS) u ćeliji. Produženi i/ili snažan oksidativni insult prevazilazi ćelijski antioksidativni odbrambreni kapacitet, dolazi do oštećenja makromolekula, gubi se ćelijska funkcija, oštećuju se membrane, što sve zajedno dovodi do smrti ćelije. Stanja organizma kao što su povećana fizička aktivnost, izloženost zagađenju čovekove okoline, ksenobioticima, pušenje itd. rezultiraju OS. Oksidativni stres, kao patofiziološki mehanizam, je potvrđen u brojnim patologijama, trovanjima i starenju. Reaktivne kiseonične vrste i reaktivne azotove vrste, endogenog ili egzogenog porekla, mogu lako da napadnu sve klase biomolekula (proteni, DNK, nezasićene masne kiseline). Narušen oksido-reduktivni milje, koji posreduje povećanju lipidne peroksidacije, promeni aktivnosti direktnih ili indirektnih antioksidativnih enzima, kao i smanjenom sadržaju neenzimskih antioksidanasa, može biti prepoznat u presimptomatskoj fazi brojnih bolesti. U tom smislu može biti pokazatelj izmenjenih metaboličkih i funkcionalnih zbivanja. U svakodnevnoj kliničko-dijagnostičkoj praksi analize parametara OS u biološkom materijalu bi trebalo da imaju svoje mesto, radi rane dijagnoze bolesti, prevencije i unapređivanja terapije. .
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Oxidative stress: Clinical diagnostic significance
VL  - 27
IS  - 4
SP  - 409
EP  - 425
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1040
ER  - 

@article{
author = "Đukić, Mirjana and Ninković, Milica and Jovanović, Marina",
year = "2008",
abstract = "Elevated free radical production and/or insufficient antioxidative defense results in cellular oxidant stress responses. Sustained and/or intense oxidative insults can overcome cell defenses resulting in accumulated damage to macromolecules, leading to loss of cell function, membrane damage, and ultimately to cell death. Oxidative stress (OS) can result from conditions including excessive physical stress, exposure to environmental pollution and xenobiotics, and smoking. Oxidative stress, as a pathophysiological mechanism, has been linked to numerous pathologies, poisonings, and the ageing process. Reactive oxygen species and reactive nitrogen species, endogenously or exogenously produced, can readily attack all classes of macromolecules (proteins, DNA, unsaturated fatty acid). The disrupted oxidative-reductive milieu proceeds via lipid peroxidation, altered antioxidative enzyme activities and depletion of non-enzymatic endogenous antioxidants, several of which can de detected in the pre-symptomatic phase of many diseases. Therefore, they could represent markers of altered metabolic and physiological homeostasis. Accordingly, from the point of view of routine clinical-diagnostic practice, it would be valuable to routinely analyze OS status parameters to earlier recognize potential disease states and provide the basis for preventative advance treatment with appropriate medicines., Povećano stvaranje slobodnih radikala i/ili nedovoljna antioksidativna zaštita dovodi do oksidativnog stre sa (OS) u ćeliji. Produženi i/ili snažan oksidativni insult prevazilazi ćelijski antioksidativni odbrambreni kapacitet, dolazi do oštećenja makromolekula, gubi se ćelijska funkcija, oštećuju se membrane, što sve zajedno dovodi do smrti ćelije. Stanja organizma kao što su povećana fizička aktivnost, izloženost zagađenju čovekove okoline, ksenobioticima, pušenje itd. rezultiraju OS. Oksidativni stres, kao patofiziološki mehanizam, je potvrđen u brojnim patologijama, trovanjima i starenju. Reaktivne kiseonične vrste i reaktivne azotove vrste, endogenog ili egzogenog porekla, mogu lako da napadnu sve klase biomolekula (proteni, DNK, nezasićene masne kiseline). Narušen oksido-reduktivni milje, koji posreduje povećanju lipidne peroksidacije, promeni aktivnosti direktnih ili indirektnih antioksidativnih enzima, kao i smanjenom sadržaju neenzimskih antioksidanasa, može biti prepoznat u presimptomatskoj fazi brojnih bolesti. U tom smislu može biti pokazatelj izmenjenih metaboličkih i funkcionalnih zbivanja. U svakodnevnoj kliničko-dijagnostičkoj praksi analize parametara OS u biološkom materijalu bi trebalo da imaju svoje mesto, radi rane dijagnoze bolesti, prevencije i unapređivanja terapije. .",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Oxidative stress: Clinical diagnostic significance",
volume = "27",
number = "4",
pages = "409-425",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1040"
}

Đukić, M., Ninković, M.,& Jovanović, M.. (2008). Oxidative stress: Clinical diagnostic significance. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 27(4), 409-425.
https://hdl.handle.net/21.15107/rcub_farfar_1040

Đukić M, Ninković M, Jovanović M. Oxidative stress: Clinical diagnostic significance. in Journal of Medical Biochemistry. 2008;27(4):409-425.
https://hdl.handle.net/21.15107/rcub_farfar_1040 .

Đukić, Mirjana, Ninković, Milica, Jovanović, Marina, "Oxidative stress: Clinical diagnostic significance" in Journal of Medical Biochemistry, 27, no. 4 (2008):409-425,
https://hdl.handle.net/21.15107/rcub_farfar_1040 .

TY  - JOUR
AU  - Dajak, Marijana
AU  - Ignjatović, Svetlana
AU  - Jovičić, Snežana
AU  - Majkić-Singh, Nada
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1097
AB  - The glomerullar filtration rate (GFR) is widely accepted as the best overall index of kidney function. GFR can be measured as the clearance of exogenous or endogenous filtration markers or clinically estimated from serum concentrations or creatinine or cystatin C. Recently, it has been recommended that an estimated GFR (eGFR) should be reported in addition to the value of filtration markers. In this study, we determined the values of eGFR, based on creatinine and cystatin C equations, in 125 healthy volunteers aged 20-75 years. Creatinine was measured by a kinetic alkaline picrate method on an ARCHITECT ci8200 analyzer (Abbott Diagnostics, Wiesbaden, Germany). Cystatin C was determined by a latex particle-enhanced immunonephelometric assay (BNII, Dade Behring, Marburg, Germany). The eGFR values were calculated for creatinine using the Modification of Diet in Renal Disease (MDRD) study equation and Rule's quadratic equation and for cystatin C according to the equation published by Hoek et al. The reference intervals for eGFRs with MDRD, Rule's quadratic and Hoek's equations were calculated nonparametrically and were determined to be 63.5-124.6 mL/min/1.73 m(2), 78.3-139.2 mL/min/1.73 m(2) and 72.2-115.6 mL/min/1.73 m(2), respectively. According to the US National Kidney Foundation, chronic kidney disease (CKD) can be defined as a GFR  lt  60 mL/min/1.73 m(2). Our results showed that healthy adults had eGFR values > 63.5 mL/min/1.73 m(2). However, it is important to note that these normal values overlap with values in stages 1 and 2 of CKD, thus an eGFR greater than 60 mL/min/1.73 m(2) does not exclude kidney disease.
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - The values of estimated glomerular filtration rate calculated with creatinine and cystatin C based equations in healthy adults
VL  - 54
IS  - 5-6
SP  - 153
EP  - 159
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1097
ER  - 

@article{
author = "Dajak, Marijana and Ignjatović, Svetlana and Jovičić, Snežana and Majkić-Singh, Nada",
year = "2008",
abstract = "The glomerullar filtration rate (GFR) is widely accepted as the best overall index of kidney function. GFR can be measured as the clearance of exogenous or endogenous filtration markers or clinically estimated from serum concentrations or creatinine or cystatin C. Recently, it has been recommended that an estimated GFR (eGFR) should be reported in addition to the value of filtration markers. In this study, we determined the values of eGFR, based on creatinine and cystatin C equations, in 125 healthy volunteers aged 20-75 years. Creatinine was measured by a kinetic alkaline picrate method on an ARCHITECT ci8200 analyzer (Abbott Diagnostics, Wiesbaden, Germany). Cystatin C was determined by a latex particle-enhanced immunonephelometric assay (BNII, Dade Behring, Marburg, Germany). The eGFR values were calculated for creatinine using the Modification of Diet in Renal Disease (MDRD) study equation and Rule's quadratic equation and for cystatin C according to the equation published by Hoek et al. The reference intervals for eGFRs with MDRD, Rule's quadratic and Hoek's equations were calculated nonparametrically and were determined to be 63.5-124.6 mL/min/1.73 m(2), 78.3-139.2 mL/min/1.73 m(2) and 72.2-115.6 mL/min/1.73 m(2), respectively. According to the US National Kidney Foundation, chronic kidney disease (CKD) can be defined as a GFR  lt  60 mL/min/1.73 m(2). Our results showed that healthy adults had eGFR values > 63.5 mL/min/1.73 m(2). However, it is important to note that these normal values overlap with values in stages 1 and 2 of CKD, thus an eGFR greater than 60 mL/min/1.73 m(2) does not exclude kidney disease.",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "The values of estimated glomerular filtration rate calculated with creatinine and cystatin C based equations in healthy adults",
volume = "54",
number = "5-6",
pages = "153-159",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1097"
}

Dajak, M., Ignjatović, S., Jovičić, S.,& Majkić-Singh, N.. (2008). The values of estimated glomerular filtration rate calculated with creatinine and cystatin C based equations in healthy adults. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 54(5-6), 153-159.
https://hdl.handle.net/21.15107/rcub_farfar_1097

Dajak M, Ignjatović S, Jovičić S, Majkić-Singh N. The values of estimated glomerular filtration rate calculated with creatinine and cystatin C based equations in healthy adults. in Clinical Laboratory. 2008;54(5-6):153-159.
https://hdl.handle.net/21.15107/rcub_farfar_1097 .

Dajak, Marijana, Ignjatović, Svetlana, Jovičić, Snežana, Majkić-Singh, Nada, "The values of estimated glomerular filtration rate calculated with creatinine and cystatin C based equations in healthy adults" in Clinical Laboratory, 54, no. 5-6 (2008):153-159,
https://hdl.handle.net/21.15107/rcub_farfar_1097 .

TY  - JOUR
AU  - Mirković, Duško
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1008
AB  - Neuroendocrine tumors derive from neuroendocrine cells, which upon specific stimulation secrete stimulation secrete hormones regulating various bodily functions. We will discuss the group of neuroendocrine tumors which is consisted of: carcinoids, endocrine pancreatic tumors, neuroblastomas medullary thyroid carcinomas and pheochromocytomas. The tumors which derived from endocrine glads will be discused, as well as, we will pay attention on tumors which derived from so called "diffuse" neuroendocrine cell system of the gastrointestinal tract. In fact, this is the largest endocrine organ of the body. About 50 different neuroendocrine cell types of the gastrointestinal tract have been indentified. One of the currently recomended diagnostic approach to these lesions is the determination of characteristic bioactive amines and peptides of neuroendocrine activity, which is changed in neoplasms. The wide spectrum of clinical symptoms are associated with lesions of endocrine glands, and dispersed neuroendocrine system, results from their collective ability to secrete an extensive array of peptide hormones and bioactive amines, that differe according to the tumor type. The main aim of this disscusion is evaluation of these potential tumor markers, and proposing using some of those markers in our conditions.
AB  - Neuroendokrini tumori vode poreklo iz neuroendokrinih ćelija, koji pod uslovima specifične stimulacije sekretuju hormone, regulišući niz različitih funkcija u organizmu. U radu je opisana grupa neuroendokrinih tumora koja se sastoji od: karcinoida endokrinih tumora pankreasa, neuroblastoma, medularnog karcinoma tiroidee i feohromocitoma. Biće diskutovani tumori koji potiču iz endokrinih žlezda, kao i oni koji vode poreklo iz takozvanog "difuznog" neuroendokrinog ćelijskog sistema gastrointestinalnog trakta. Radi se o najvećem endokrinom organu u organizmu. Oko 50 različitih neuroendokrinih ćelijskih tipova gastrointestinalnog trakta je indentifikovano. Važan dijagnostički segment u tretmanu ovih tumora, je određivanje biogenih amina i peptida, čija je aktivnost izmenjena kod pojave neoplazmi. Širok je spektar kliničkih simptoma kod pojave ove vrste tumora, a svi su posledica sposobnosti tumora da sekretuju povećane količine peptinih hormona i biogenih amina. Glavni ciljevi ovog teksta su procena važnosti ove grupe tumorskih markera, kao i predlozi za njihovo korišćenje u našim uslovima.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Recommedition for apllication and determination tumor markers of neuroendocrine system
T1  - Preporuke za primenu i odredivanje tumorskih markera kod neoplazmi neuroendokrinog sistema
VL  - 26
IS  - 2
SP  - 157
EP  - 164
DO  - 10.2478/v10011-007-0019-3
ER  - 

@article{
author = "Mirković, Duško",
year = "2007",
abstract = "Neuroendocrine tumors derive from neuroendocrine cells, which upon specific stimulation secrete stimulation secrete hormones regulating various bodily functions. We will discuss the group of neuroendocrine tumors which is consisted of: carcinoids, endocrine pancreatic tumors, neuroblastomas medullary thyroid carcinomas and pheochromocytomas. The tumors which derived from endocrine glads will be discused, as well as, we will pay attention on tumors which derived from so called "diffuse" neuroendocrine cell system of the gastrointestinal tract. In fact, this is the largest endocrine organ of the body. About 50 different neuroendocrine cell types of the gastrointestinal tract have been indentified. One of the currently recomended diagnostic approach to these lesions is the determination of characteristic bioactive amines and peptides of neuroendocrine activity, which is changed in neoplasms. The wide spectrum of clinical symptoms are associated with lesions of endocrine glands, and dispersed neuroendocrine system, results from their collective ability to secrete an extensive array of peptide hormones and bioactive amines, that differe according to the tumor type. The main aim of this disscusion is evaluation of these potential tumor markers, and proposing using some of those markers in our conditions., Neuroendokrini tumori vode poreklo iz neuroendokrinih ćelija, koji pod uslovima specifične stimulacije sekretuju hormone, regulišući niz različitih funkcija u organizmu. U radu je opisana grupa neuroendokrinih tumora koja se sastoji od: karcinoida endokrinih tumora pankreasa, neuroblastoma, medularnog karcinoma tiroidee i feohromocitoma. Biće diskutovani tumori koji potiču iz endokrinih žlezda, kao i oni koji vode poreklo iz takozvanog "difuznog" neuroendokrinog ćelijskog sistema gastrointestinalnog trakta. Radi se o najvećem endokrinom organu u organizmu. Oko 50 različitih neuroendokrinih ćelijskih tipova gastrointestinalnog trakta je indentifikovano. Važan dijagnostički segment u tretmanu ovih tumora, je određivanje biogenih amina i peptida, čija je aktivnost izmenjena kod pojave neoplazmi. Širok je spektar kliničkih simptoma kod pojave ove vrste tumora, a svi su posledica sposobnosti tumora da sekretuju povećane količine peptinih hormona i biogenih amina. Glavni ciljevi ovog teksta su procena važnosti ove grupe tumorskih markera, kao i predlozi za njihovo korišćenje u našim uslovima.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Recommedition for apllication and determination tumor markers of neuroendocrine system, Preporuke za primenu i odredivanje tumorskih markera kod neoplazmi neuroendokrinog sistema",
volume = "26",
number = "2",
pages = "157-164",
doi = "10.2478/v10011-007-0019-3"
}

Mirković, D.. (2007). Recommedition for apllication and determination tumor markers of neuroendocrine system. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 26(2), 157-164.
https://doi.org/10.2478/v10011-007-0019-3

Mirković D. Recommedition for apllication and determination tumor markers of neuroendocrine system. in Journal of Medical Biochemistry. 2007;26(2):157-164.
doi:10.2478/v10011-007-0019-3 .

Mirković, Duško, "Recommedition for apllication and determination tumor markers of neuroendocrine system" in Journal of Medical Biochemistry, 26, no. 2 (2007):157-164,
https://doi.org/10.2478/v10011-007-0019-3 . .

TY  - JOUR
AU  - Ćurčić-Jovanović, Marijana
AU  - Đukić, Mirjana
AU  - Vasiljević, Ivana
AU  - Ninković, Milica
AU  - Jovanović, Marina
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1021
AB  - This work was a part of an initial study regarding the involvement of reactive nitrogen species (RNS) in paraquat (PQ) neurotoxicity. The nitrate concentration in the vulnerable regions of the brain (cortex, striatum and hippocampus) of Wistar rats was used as a measure of nitric oxide (NO) production or catabolism of the formed RNS. The tissue homogenates were deproteinized with acetonitrile and then centrifuged. Nitrate was measured in filtrated supernatants by simple and rapid isocratic ion-exchange high performance liquid chromatography with UV detection (IE-HPLC-UV) at 214 nm. The mobile phase (pH 8.5) consisted of borate buffer/gluconate concentrate, methanol, acetonitrile and deionized water (2:12:12:74, v/v/v/v), and the flow rate was 1.3 mL/min. Physiological nitrate levels (18.8 ± 6.1 nmol/mg of proteins), as well as a diverse range of nitrate concentrations could be determined with good precision (CV = 2.2 %) and accuracy (recovery of spiked samples was 99 ± 4%) in the brain tissue homogenates. Linearity was achieved in the range of nitrate from 0-80 μM. The retention time of nitrate anion was 5.3 ± 0.3 min. .
AB  - Prezentovani rad je deo započete studije o uključenosti reaktivnih vrsta azota (RNS) u neurotoksičnost parakvata (PQ). Sadržaj nitrata u selektivno osetljivim moždanim regijama (cortex, striatum i hippocampus) Wistar pacova može se koristiti kao merilo produkcije azotmonoksida ili katabolizma drugih RNS. Homogenizati moždanog tkiva su najpre deproteinizovani, zatim centrifugirani. Nitrati su određivani u filtriranom supernatantu brzom i jednostavnom izokratskom metodom visoko efikasne tečne hromatografije sa diode-array detekcijom (IE-HPLC-UV) na 214 nm. Korišćena je mobilna faza sastava: boratni pufer/glukonat koncentrat : metanol : acetonitril : dejonizovana voda (2:12:12:74, v/v/v/v), pH 8,5, pri protoku 1,3 mL/min. Širok opseg koncentracija nitrata kao i njihovi fiziološki nivoi (18,8 ± 6,1 nmol/mg proteina) mogu se meriti sa dobrom preciznošću (CV = 2,2%) i tačnošću (recovery opterećenih uzoraka 99 ± 4%) u homogenizatima moždanih tkiva. Linearnost je dobijena u opsegu 0-80 μmol/L nitrata dok je retenciono vreme bilo 5,3 ± 0,3 min. .
PB  - Srpsko hemijsko društvo, Beograd
T2  - Journal of the Serbian Chemical Society
T1  - Determination of nitrate by the IE-HPLC-UV method in the brain tissues of Wistar rats poisoned with paraquat
T1  - Određivanje nitrata IE-HPLC-UV metodom u moždanim tkivima Wistar pacova trovanih parakvatom
VL  - 72
IS  - 4
SP  - 347
EP  - 356
DO  - 10.2298/JSC0704347C
ER  - 

@article{
author = "Ćurčić-Jovanović, Marijana and Đukić, Mirjana and Vasiljević, Ivana and Ninković, Milica and Jovanović, Marina",
year = "2007",
abstract = "This work was a part of an initial study regarding the involvement of reactive nitrogen species (RNS) in paraquat (PQ) neurotoxicity. The nitrate concentration in the vulnerable regions of the brain (cortex, striatum and hippocampus) of Wistar rats was used as a measure of nitric oxide (NO) production or catabolism of the formed RNS. The tissue homogenates were deproteinized with acetonitrile and then centrifuged. Nitrate was measured in filtrated supernatants by simple and rapid isocratic ion-exchange high performance liquid chromatography with UV detection (IE-HPLC-UV) at 214 nm. The mobile phase (pH 8.5) consisted of borate buffer/gluconate concentrate, methanol, acetonitrile and deionized water (2:12:12:74, v/v/v/v), and the flow rate was 1.3 mL/min. Physiological nitrate levels (18.8 ± 6.1 nmol/mg of proteins), as well as a diverse range of nitrate concentrations could be determined with good precision (CV = 2.2 %) and accuracy (recovery of spiked samples was 99 ± 4%) in the brain tissue homogenates. Linearity was achieved in the range of nitrate from 0-80 μM. The retention time of nitrate anion was 5.3 ± 0.3 min. ., Prezentovani rad je deo započete studije o uključenosti reaktivnih vrsta azota (RNS) u neurotoksičnost parakvata (PQ). Sadržaj nitrata u selektivno osetljivim moždanim regijama (cortex, striatum i hippocampus) Wistar pacova može se koristiti kao merilo produkcije azotmonoksida ili katabolizma drugih RNS. Homogenizati moždanog tkiva su najpre deproteinizovani, zatim centrifugirani. Nitrati su određivani u filtriranom supernatantu brzom i jednostavnom izokratskom metodom visoko efikasne tečne hromatografije sa diode-array detekcijom (IE-HPLC-UV) na 214 nm. Korišćena je mobilna faza sastava: boratni pufer/glukonat koncentrat : metanol : acetonitril : dejonizovana voda (2:12:12:74, v/v/v/v), pH 8,5, pri protoku 1,3 mL/min. Širok opseg koncentracija nitrata kao i njihovi fiziološki nivoi (18,8 ± 6,1 nmol/mg proteina) mogu se meriti sa dobrom preciznošću (CV = 2,2%) i tačnošću (recovery opterećenih uzoraka 99 ± 4%) u homogenizatima moždanih tkiva. Linearnost je dobijena u opsegu 0-80 μmol/L nitrata dok je retenciono vreme bilo 5,3 ± 0,3 min. .",
publisher = "Srpsko hemijsko društvo, Beograd",
journal = "Journal of the Serbian Chemical Society",
title = "Determination of nitrate by the IE-HPLC-UV method in the brain tissues of Wistar rats poisoned with paraquat, Određivanje nitrata IE-HPLC-UV metodom u moždanim tkivima Wistar pacova trovanih parakvatom",
volume = "72",
number = "4",
pages = "347-356",
doi = "10.2298/JSC0704347C"
}

Ćurčić-Jovanović, M., Đukić, M., Vasiljević, I., Ninković, M.,& Jovanović, M.. (2007). Determination of nitrate by the IE-HPLC-UV method in the brain tissues of Wistar rats poisoned with paraquat. in Journal of the Serbian Chemical Society
Srpsko hemijsko društvo, Beograd., 72(4), 347-356.
https://doi.org/10.2298/JSC0704347C

Ćurčić-Jovanović M, Đukić M, Vasiljević I, Ninković M, Jovanović M. Determination of nitrate by the IE-HPLC-UV method in the brain tissues of Wistar rats poisoned with paraquat. in Journal of the Serbian Chemical Society. 2007;72(4):347-356.
doi:10.2298/JSC0704347C .

Ćurčić-Jovanović, Marijana, Đukić, Mirjana, Vasiljević, Ivana, Ninković, Milica, Jovanović, Marina, "Determination of nitrate by the IE-HPLC-UV method in the brain tissues of Wistar rats poisoned with paraquat" in Journal of the Serbian Chemical Society, 72, no. 4 (2007):347-356,
https://doi.org/10.2298/JSC0704347C . .

TY  - JOUR
AU  - Đukić, Mirjana
AU  - Ćurčić-Jovanović, Marijana
AU  - Ninković, Milica
AU  - Vasijević, Ivana
AU  - Jovanović, Marina
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/908
AB  - The role of nitric oxide (NO) in paraquat (PQ)-induced neurotoxicity is still not fully understood. In this study we used N-G-nitro-L-arginine methyl ester (L-NAME), a non-selective nitric oxide synthase (NOS) inhibitor, in order to examine the effects of NO, reactive oxygen species (ROS) generation and lipid peroxidation (LPO) development during PQ-mediated neurotoxicity. Oxidative stress development in the striatum of Wistar rats intrastriatally (i.s.) poisoned with PQ (and in some cases pre-treated with L-NAME) was investigated by measuring superoxide anion (O-2(center dot-)), malondialdehyde (MDA) and nitrate (NO3-), 30 min, 24 hours and 7 days after treatment. L-NAME pretreatment provided the possibility to distinguish the role of ROS from reactive nitrogen species (RNS) in oxidative stress development induced by PQ. Our results confirm the involvement of NO in PQ-mediated neurotoxicity and reduced LPO by L-NAME pretreatment implying that the latter has a protective role.
PB  - Inst Agricultural Medicine, Lublin
T2  - Annals of Agricultural and Environmental Medicine
T1  - The role of nitric oxide in paraquat-induced oxidative stress in rat striatum
VL  - 14
IS  - 2
SP  - 247
EP  - 252
UR  - https://hdl.handle.net/21.15107/rcub_farfar_908
ER  - 

@article{
author = "Đukić, Mirjana and Ćurčić-Jovanović, Marijana and Ninković, Milica and Vasijević, Ivana and Jovanović, Marina",
year = "2007",
abstract = "The role of nitric oxide (NO) in paraquat (PQ)-induced neurotoxicity is still not fully understood. In this study we used N-G-nitro-L-arginine methyl ester (L-NAME), a non-selective nitric oxide synthase (NOS) inhibitor, in order to examine the effects of NO, reactive oxygen species (ROS) generation and lipid peroxidation (LPO) development during PQ-mediated neurotoxicity. Oxidative stress development in the striatum of Wistar rats intrastriatally (i.s.) poisoned with PQ (and in some cases pre-treated with L-NAME) was investigated by measuring superoxide anion (O-2(center dot-)), malondialdehyde (MDA) and nitrate (NO3-), 30 min, 24 hours and 7 days after treatment. L-NAME pretreatment provided the possibility to distinguish the role of ROS from reactive nitrogen species (RNS) in oxidative stress development induced by PQ. Our results confirm the involvement of NO in PQ-mediated neurotoxicity and reduced LPO by L-NAME pretreatment implying that the latter has a protective role.",
publisher = "Inst Agricultural Medicine, Lublin",
journal = "Annals of Agricultural and Environmental Medicine",
title = "The role of nitric oxide in paraquat-induced oxidative stress in rat striatum",
volume = "14",
number = "2",
pages = "247-252",
url = "https://hdl.handle.net/21.15107/rcub_farfar_908"
}

Đukić, M., Ćurčić-Jovanović, M., Ninković, M., Vasijević, I.,& Jovanović, M.. (2007). The role of nitric oxide in paraquat-induced oxidative stress in rat striatum. in Annals of Agricultural and Environmental Medicine
Inst Agricultural Medicine, Lublin., 14(2), 247-252.
https://hdl.handle.net/21.15107/rcub_farfar_908

Đukić M, Ćurčić-Jovanović M, Ninković M, Vasijević I, Jovanović M. The role of nitric oxide in paraquat-induced oxidative stress in rat striatum. in Annals of Agricultural and Environmental Medicine. 2007;14(2):247-252.
https://hdl.handle.net/21.15107/rcub_farfar_908 .

Đukić, Mirjana, Ćurčić-Jovanović, Marijana, Ninković, Milica, Vasijević, Ivana, Jovanović, Marina, "The role of nitric oxide in paraquat-induced oxidative stress in rat striatum" in Annals of Agricultural and Environmental Medicine, 14, no. 2 (2007):247-252,
https://hdl.handle.net/21.15107/rcub_farfar_908 .

TY  - JOUR
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1022
AB  - The goal of every operation or production system is to generate a useful product. Most quality-control methods were initially developed to aid manufacturing. This is not surprising because high volume production typically requires many repetitions involving a controlled sequence of operations. Not all of the many approaches to quality control are equally effective. Nonconformities in laboratory testing are caused basically by excessive process variation and mistakes. A critical limitation of the statistical quality control - based methods is that they are ineffective in detecting and controlling mistakes, the dominant source of nonconformities in most organizations today. Statistical quality control can effectively control process variation, but it cannot detect or prevent most mistakes. Six Sigma belongs to statistical quality control and provides a new methodology for measuring process performance and refines earlier methodologies for making process improvements. Six Sigma Quality Management is slowly making inroads in healthcare organizations and offers a real hope for improving quality management thinking and processes. The reason is that Six Sigma focuses on defects, which in turn requires that goals for good quality be defined. Six Sigma provides a universal methodology for measuring quality by counting the defects, determining the defect rate as »defects per million« or »DPM«, and then converting DPM to a sigma-metric (by use of standard tables available in any Six Sigma text). To reduce (and oversimplify) Six Sigma, there now are »Sigma metrics« that provide a universal benchmark for process performance. The performance of all processes can be characterized on the »Sigma scale.« Values typically range from 2 to 6, where the goal for »world class quality« is 6. Based on the data from real-world health laboratory is an obvious statement that current instrumentation performs well. The new generation of clinical analyzers have achieved some high Sigma metrics. Customers in healthcare are going to enjoy a new era empowerment with instruments and methods that perform at 6 Sigma or higher.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Application of six sigma in control of health laboratories
T1  - Primena »six sigma« u kontroli kvaliteta zdravstvenih laboratorija
VL  - 26
IS  - 3
SP  - 196
EP  - 200
DO  - 10.2478/v10011-007-0022-8
ER  - 

@article{
author = "Ignjatović, Svetlana and Majkić-Singh, Nada",
year = "2007",
abstract = "The goal of every operation or production system is to generate a useful product. Most quality-control methods were initially developed to aid manufacturing. This is not surprising because high volume production typically requires many repetitions involving a controlled sequence of operations. Not all of the many approaches to quality control are equally effective. Nonconformities in laboratory testing are caused basically by excessive process variation and mistakes. A critical limitation of the statistical quality control - based methods is that they are ineffective in detecting and controlling mistakes, the dominant source of nonconformities in most organizations today. Statistical quality control can effectively control process variation, but it cannot detect or prevent most mistakes. Six Sigma belongs to statistical quality control and provides a new methodology for measuring process performance and refines earlier methodologies for making process improvements. Six Sigma Quality Management is slowly making inroads in healthcare organizations and offers a real hope for improving quality management thinking and processes. The reason is that Six Sigma focuses on defects, which in turn requires that goals for good quality be defined. Six Sigma provides a universal methodology for measuring quality by counting the defects, determining the defect rate as »defects per million« or »DPM«, and then converting DPM to a sigma-metric (by use of standard tables available in any Six Sigma text). To reduce (and oversimplify) Six Sigma, there now are »Sigma metrics« that provide a universal benchmark for process performance. The performance of all processes can be characterized on the »Sigma scale.« Values typically range from 2 to 6, where the goal for »world class quality« is 6. Based on the data from real-world health laboratory is an obvious statement that current instrumentation performs well. The new generation of clinical analyzers have achieved some high Sigma metrics. Customers in healthcare are going to enjoy a new era empowerment with instruments and methods that perform at 6 Sigma or higher.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Application of six sigma in control of health laboratories, Primena »six sigma« u kontroli kvaliteta zdravstvenih laboratorija",
volume = "26",
number = "3",
pages = "196-200",
doi = "10.2478/v10011-007-0022-8"
}

Ignjatović, S.,& Majkić-Singh, N.. (2007). Application of six sigma in control of health laboratories. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 26(3), 196-200.
https://doi.org/10.2478/v10011-007-0022-8

Ignjatović S, Majkić-Singh N. Application of six sigma in control of health laboratories. in Journal of Medical Biochemistry. 2007;26(3):196-200.
doi:10.2478/v10011-007-0022-8 .

Ignjatović, Svetlana, Majkić-Singh, Nada, "Application of six sigma in control of health laboratories" in Journal of Medical Biochemistry, 26, no. 3 (2007):196-200,
https://doi.org/10.2478/v10011-007-0022-8 . .

TY  - JOUR
AU  - Dajak, Marijana
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1011
AB  - The glomerular filtration rate (GFR) is widely accepted as the best overall measure of kidney function. American National Kidney Foundation guidelines define chronic kidney disease (CKD) by either a GFR of less than 60 mL/min/1.73 m2 or the presence of kidney damage, regardless of the cause, for 3 or more months, and classify stages of CKD severity according to GFR. GFR can be measured as the urinary or plasma clearance of exogenous filtration markers such as inulin. However, because of difficulty in use, expenses and radiation exposure, these methods have limited use in the routine laboratories. Creatinine clearance may be a useful alternative when exogenous markers are not available, but timed urinary collection is not convenient for patients and is susceptible to error during collection. GFR is often estimated clinically from serum concentrations of endogenous creatinine or cystatin C. Serum cystatin C has not yet been adequately evaluated as an index of GFR, and serum creatinine is affected by the GFR and by factors independent of GFR, including age, sex, race, body size, diet, certain drugs and laboratory analytical methods. According to National Kidney Foundation clinical guidelines, clinical laboratories should report an estimated GFR calculated from prediction equations, in addition to reporting the serum marker value. The currently recommended estimating equation was developed from the Modification of Diet in Renal Disease (MDRD) study. This equation uses age, sex, race (African-American vs. non-African-American), and serum creatinine concentration, and does not require a body weight variable because it normalizes GFR for a standard body surface area of 1.73 m 2. To achieve improved accuracy of calculated GFR with this equation, it is recommended that commercial creatinine methods should be calibrated against certified reference material and should be traceable to IDMS (isotope dilution mass spectrometry) methodology. MDRD equation has been shown to be useful for CKD patients, but its use is still unclear for people with low values for serum creatinine and high values for GFR, including healthy individuals, children and pregnant women. Validation studies are in progress to evaluate the MDRD equation for other ethnic groups and various disease conditions.
AB  - Brzina glomerularne filtracije (GFR) je široko prihvaćena kao najbolja opšta mera funkcije bubrega. Vodiči američke Nacionalne fondacije za bubreg definiš u hroničnu bubrežnu bolest (HBB) bilo sa vrednošću GFR koja je manja od 60 mL/min/1,73 m2 ili sa prisustvom oštećenja bubrega, bez obzira na uzrok, u toku 3 ili više meseci i klasifikuju stadijume težine HBB prema GFR. GFR se može meriti kao urinarni ili plazma klirens egzogenih filtracionih markera kao što je inulin. Međutim, zbog teškoća u primeni, troškova i radijacionog izlaganja, ove metode imaju ograničenu upotrebu u rutinskim laboratorijama. Klirens kreatinina može biti korisna alternativa kada egzogeni markeri nisu dostupni, ali sakupljanje urina u vremenskim intervalima nije pogodno za pacijente i osetljivo je na grešku pri sakupljanju. GFR se često procenjuje klinički iz serumskih koncentracija egzogenog kreatinina ili cistatina C. Cistatin C u serumu još uvek nije adekvatno procenjen kao indeks GFR, a na kreatinin u serumu utiču GFR i faktori nezavisni od GFR, uključujući godine pol, rasu, telesnu veličinu, ishranu, izvesne lekove i laboratorijske analitičke metode. Prema kliničkim vodičima Nacionalne fondacije za bubreg kliničke laboratorije bi trebalo da izdaju "procenjenu " GFR (estimated GFR) izračunatu iz prediktivnih jednačina, kao dodatak izveštavanja vrednosti markera u serumu. Trenutno preporučena jednačina za procenu je razvijena iz MDRD (Modification of Diet in Renal Disease) studije. Ova jednačina koristi godine, pol, rasu (afro-američka prema ne-afro-američkoj) i koncentraciju kreatinina u serumu, a ne zahteva varijablu za telesnu težinu zato što normalizuje GFR za standardnu telesnu površinu od 1,73 m2. Da bi se postigla poboljšana tačnost preračunate GFR sa ovom jednačinom, preporučuje se da komercijalne metode za kreatinin budu kalibrisane prema sertifikovanim referentnim materijalima i sledljive sa IDMS (isotope dilution mass spectrometry) metodologijom. Za MDRD jednačinu je pokazano da je korisna za pacijente sa HBB, ali njena upotreba je još uvek nejasna za ljude sa niskim vrednostima kreatinina u serumu i visokim vrednostima za GFR, uključujući zdrave pojedince, decu i trudnice. Validacione studije su u razvoju kako bi se procenila MDRD jednačina za druge etničke grupe i različita bolesna stanja.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Renal function: Estimation of glomerular filtration rate
T1  - Funkcija bubrega - Procena brzine glomerularne filtracije
VL  - 26
IS  - 1
SP  - 51
EP  - 57
DO  - 10.2478/v10011-007-0010-z
ER  - 

@article{
author = "Dajak, Marijana and Ignjatović, Svetlana and Majkić-Singh, Nada",
year = "2007",
abstract = "The glomerular filtration rate (GFR) is widely accepted as the best overall measure of kidney function. American National Kidney Foundation guidelines define chronic kidney disease (CKD) by either a GFR of less than 60 mL/min/1.73 m2 or the presence of kidney damage, regardless of the cause, for 3 or more months, and classify stages of CKD severity according to GFR. GFR can be measured as the urinary or plasma clearance of exogenous filtration markers such as inulin. However, because of difficulty in use, expenses and radiation exposure, these methods have limited use in the routine laboratories. Creatinine clearance may be a useful alternative when exogenous markers are not available, but timed urinary collection is not convenient for patients and is susceptible to error during collection. GFR is often estimated clinically from serum concentrations of endogenous creatinine or cystatin C. Serum cystatin C has not yet been adequately evaluated as an index of GFR, and serum creatinine is affected by the GFR and by factors independent of GFR, including age, sex, race, body size, diet, certain drugs and laboratory analytical methods. According to National Kidney Foundation clinical guidelines, clinical laboratories should report an estimated GFR calculated from prediction equations, in addition to reporting the serum marker value. The currently recommended estimating equation was developed from the Modification of Diet in Renal Disease (MDRD) study. This equation uses age, sex, race (African-American vs. non-African-American), and serum creatinine concentration, and does not require a body weight variable because it normalizes GFR for a standard body surface area of 1.73 m 2. To achieve improved accuracy of calculated GFR with this equation, it is recommended that commercial creatinine methods should be calibrated against certified reference material and should be traceable to IDMS (isotope dilution mass spectrometry) methodology. MDRD equation has been shown to be useful for CKD patients, but its use is still unclear for people with low values for serum creatinine and high values for GFR, including healthy individuals, children and pregnant women. Validation studies are in progress to evaluate the MDRD equation for other ethnic groups and various disease conditions., Brzina glomerularne filtracije (GFR) je široko prihvaćena kao najbolja opšta mera funkcije bubrega. Vodiči američke Nacionalne fondacije za bubreg definiš u hroničnu bubrežnu bolest (HBB) bilo sa vrednošću GFR koja je manja od 60 mL/min/1,73 m2 ili sa prisustvom oštećenja bubrega, bez obzira na uzrok, u toku 3 ili više meseci i klasifikuju stadijume težine HBB prema GFR. GFR se može meriti kao urinarni ili plazma klirens egzogenih filtracionih markera kao što je inulin. Međutim, zbog teškoća u primeni, troškova i radijacionog izlaganja, ove metode imaju ograničenu upotrebu u rutinskim laboratorijama. Klirens kreatinina može biti korisna alternativa kada egzogeni markeri nisu dostupni, ali sakupljanje urina u vremenskim intervalima nije pogodno za pacijente i osetljivo je na grešku pri sakupljanju. GFR se često procenjuje klinički iz serumskih koncentracija egzogenog kreatinina ili cistatina C. Cistatin C u serumu još uvek nije adekvatno procenjen kao indeks GFR, a na kreatinin u serumu utiču GFR i faktori nezavisni od GFR, uključujući godine pol, rasu, telesnu veličinu, ishranu, izvesne lekove i laboratorijske analitičke metode. Prema kliničkim vodičima Nacionalne fondacije za bubreg kliničke laboratorije bi trebalo da izdaju "procenjenu " GFR (estimated GFR) izračunatu iz prediktivnih jednačina, kao dodatak izveštavanja vrednosti markera u serumu. Trenutno preporučena jednačina za procenu je razvijena iz MDRD (Modification of Diet in Renal Disease) studije. Ova jednačina koristi godine, pol, rasu (afro-američka prema ne-afro-američkoj) i koncentraciju kreatinina u serumu, a ne zahteva varijablu za telesnu težinu zato što normalizuje GFR za standardnu telesnu površinu od 1,73 m2. Da bi se postigla poboljšana tačnost preračunate GFR sa ovom jednačinom, preporučuje se da komercijalne metode za kreatinin budu kalibrisane prema sertifikovanim referentnim materijalima i sledljive sa IDMS (isotope dilution mass spectrometry) metodologijom. Za MDRD jednačinu je pokazano da je korisna za pacijente sa HBB, ali njena upotreba je još uvek nejasna za ljude sa niskim vrednostima kreatinina u serumu i visokim vrednostima za GFR, uključujući zdrave pojedince, decu i trudnice. Validacione studije su u razvoju kako bi se procenila MDRD jednačina za druge etničke grupe i različita bolesna stanja.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Renal function: Estimation of glomerular filtration rate, Funkcija bubrega - Procena brzine glomerularne filtracije",
volume = "26",
number = "1",
pages = "51-57",
doi = "10.2478/v10011-007-0010-z"
}

Dajak, M., Ignjatović, S.,& Majkić-Singh, N.. (2007). Renal function: Estimation of glomerular filtration rate. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 26(1), 51-57.
https://doi.org/10.2478/v10011-007-0010-z

Dajak M, Ignjatović S, Majkić-Singh N. Renal function: Estimation of glomerular filtration rate. in Journal of Medical Biochemistry. 2007;26(1):51-57.
doi:10.2478/v10011-007-0010-z .

Dajak, Marijana, Ignjatović, Svetlana, Majkić-Singh, Nada, "Renal function: Estimation of glomerular filtration rate" in Journal of Medical Biochemistry, 26, no. 1 (2007):51-57,
https://doi.org/10.2478/v10011-007-0010-z . .

TY  - JOUR
AU  - Jovičić, Snežana
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1010
AB  - Numerous studies have shown that the major risk factors for coronary heart disease (cigarette smoking, hypertension, elevated serum total cholesterol and low-density lipoprotein cholesterol - LDL, low serum high-density lipoprotein cholesterol - HDL, diabetes mellitus and advancing age), are additive in predictive power. Accordingly, the total risk of a person can be estimated by summing up the risk imparted by each of the major risk factors. Using data obtained from population studies, various risk assessment algorithms have been developed. The aim of this study was to compare the two most common risk scores. Risk assessment for determining 10-year risk in 185 healthy, asymptomatic individuals of both sexes, 30-85 years old, was carried out according to both Framingham (FRS) and SCORE risk scoring. The risk factors included in the calculation of 10-year risk are gender, age, total cholesterol, HDL-cholesterol, systolic blood pressure, treatment for hypertension and cigarette smoking. The determinations of total cholesterol and HDL-cholesterol were made in sera collected after a 12h fasting period using an Olympus AU2700 automated analyzer. The Framingham risk score was determined using an electronic calculator - ATP III Risk Estimator, and the risk status according to SCORE was obtained using charts for the 10-year risk in populations at high risk. Among 185 participants, in 152 (82%) 10-year risk for Coronary Heart Disease (CHD) death was  lt 10%, 24 (13%) had intermediate and 9 (5%) had high risk (>20%) according to FRS. According to SCORE, 110 (60%) participants had  lt 1%, 56 (30%) had 1-5% and 19 (10%) had >5% of 10-year risk for cardiovascular death. Different categories of risk were assigned to ∼30% of individuals according to different risk assessment models. Differences in risk classification when using two different risk assessment algorithms can be explained with several important issues including different endpoints, consideration of interactions and incorporation of antihypertensive use. It is important to note that neither FRS nor SCORE have been appropriately adjusted for our population, according to the national cardiovascular mortality rate.
AB  - Brojne studije su pokazale aditivnu prediktivnu vrednost glavnih faktora rizika za pojavu koronarne srčane bolesti (pušenje, hipertenzija, povišena koncentracija ukupnog i LDL-holesterola i niska koncentracija HDL-holesterola u serumu, dijabetes i starost). Na osnovu toga, ukupan rizik za jednu osobu može se proceniti sumiranjem rizika koji nosi svaki glavni faktor rizika pojedinačno. Veliki broj algoritama za procenu rizika razvijen je na osnovu podataka dobijenih iz populacionih studija. Cilj ovog rada bio je poređenje dva najčešće korišćena rizik skora. Za 185 zdravih, asimptomatskih osoba oba pola, 30-85 godina starosti, procenjen je rizik od pojave kardiovaskularnih bolesti (KVB) u narednih 10 godina prema "Framingham" (FRS) i SCORE sistemu. Faktori rizika koji su uključeni u izračunavanje 10-godišnjeg rizika su pol starost, ukupan i HDLholesterol, sistolni krvni pritisak, terapija antihipertenzivima i pušenje. Ukupan i HDL-holesterol određivani su u uzorcima seruma, dobijenim posle 12 sati gladovanja, na biohemijskom analizatoru Olympus AU2700. FRS je izračunavan pomoću programa "ATP III Risk Estimator", a SCORE rizik je dobijen pomoću tablica za 10-godišnji rizik za populacije sa visokim rizikom. Od 185 učesnika, kod 152 (82%) 10- godišnji rizik za srčanu smrt bio je  lt 10%, 24 (13%) je imalo srednji, a 9 (5%) je imalo visoki rizik (≥20%) na osnovu FRS. Prema SCORE-u, 110 učesnika (60%) imalo je 10- godišnji rizik od kardiovaskularne smrti  lt 1%, 56 (30%) je imalo 1-5% rizika, dok je kod 19 osoba (10%) identifikovan visok rizik (≥5%). Oko 30% ispitanika svrstano je u različite kategorije rizika na osnovu različitih modela za procenu rizika. Razlike u klasifikaciji na osnovu kardiovaskularnog rizika, koje se dobijaju korišćenjem dva različita algoritma za procenu rizika, mogu se objasniti time što ovi sistemi koriste različite krajnje ishode bolesti i što se razlikuju po uticaju interakcija i uzimanju u obzir upotrebe antihipertenzivnih lekova. Važno je naglasiti da ni FRS ni SCORE nisu prilagođeni našoj populaciji, na osnovu nacionalne stope mortaliteta od KVB.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Comparison of two different methods for cardiovascular risk assessment: Framingham risk score and SCORE system
T1  - Poređenje dve metode procene kardiovaskularnog rizika - 'Framingham' rizik skor i 'Score' sistem
VL  - 26
IS  - 2
SP  - 94
EP  - 97
DO  - 10.2478/v10011-007-0012-x
ER  - 

@article{
author = "Jovičić, Snežana and Ignjatović, Svetlana and Majkić-Singh, Nada",
year = "2007",
abstract = "Numerous studies have shown that the major risk factors for coronary heart disease (cigarette smoking, hypertension, elevated serum total cholesterol and low-density lipoprotein cholesterol - LDL, low serum high-density lipoprotein cholesterol - HDL, diabetes mellitus and advancing age), are additive in predictive power. Accordingly, the total risk of a person can be estimated by summing up the risk imparted by each of the major risk factors. Using data obtained from population studies, various risk assessment algorithms have been developed. The aim of this study was to compare the two most common risk scores. Risk assessment for determining 10-year risk in 185 healthy, asymptomatic individuals of both sexes, 30-85 years old, was carried out according to both Framingham (FRS) and SCORE risk scoring. The risk factors included in the calculation of 10-year risk are gender, age, total cholesterol, HDL-cholesterol, systolic blood pressure, treatment for hypertension and cigarette smoking. The determinations of total cholesterol and HDL-cholesterol were made in sera collected after a 12h fasting period using an Olympus AU2700 automated analyzer. The Framingham risk score was determined using an electronic calculator - ATP III Risk Estimator, and the risk status according to SCORE was obtained using charts for the 10-year risk in populations at high risk. Among 185 participants, in 152 (82%) 10-year risk for Coronary Heart Disease (CHD) death was  lt 10%, 24 (13%) had intermediate and 9 (5%) had high risk (>20%) according to FRS. According to SCORE, 110 (60%) participants had  lt 1%, 56 (30%) had 1-5% and 19 (10%) had >5% of 10-year risk for cardiovascular death. Different categories of risk were assigned to ∼30% of individuals according to different risk assessment models. Differences in risk classification when using two different risk assessment algorithms can be explained with several important issues including different endpoints, consideration of interactions and incorporation of antihypertensive use. It is important to note that neither FRS nor SCORE have been appropriately adjusted for our population, according to the national cardiovascular mortality rate., Brojne studije su pokazale aditivnu prediktivnu vrednost glavnih faktora rizika za pojavu koronarne srčane bolesti (pušenje, hipertenzija, povišena koncentracija ukupnog i LDL-holesterola i niska koncentracija HDL-holesterola u serumu, dijabetes i starost). Na osnovu toga, ukupan rizik za jednu osobu može se proceniti sumiranjem rizika koji nosi svaki glavni faktor rizika pojedinačno. Veliki broj algoritama za procenu rizika razvijen je na osnovu podataka dobijenih iz populacionih studija. Cilj ovog rada bio je poređenje dva najčešće korišćena rizik skora. Za 185 zdravih, asimptomatskih osoba oba pola, 30-85 godina starosti, procenjen je rizik od pojave kardiovaskularnih bolesti (KVB) u narednih 10 godina prema "Framingham" (FRS) i SCORE sistemu. Faktori rizika koji su uključeni u izračunavanje 10-godišnjeg rizika su pol starost, ukupan i HDLholesterol, sistolni krvni pritisak, terapija antihipertenzivima i pušenje. Ukupan i HDL-holesterol određivani su u uzorcima seruma, dobijenim posle 12 sati gladovanja, na biohemijskom analizatoru Olympus AU2700. FRS je izračunavan pomoću programa "ATP III Risk Estimator", a SCORE rizik je dobijen pomoću tablica za 10-godišnji rizik za populacije sa visokim rizikom. Od 185 učesnika, kod 152 (82%) 10- godišnji rizik za srčanu smrt bio je  lt 10%, 24 (13%) je imalo srednji, a 9 (5%) je imalo visoki rizik (≥20%) na osnovu FRS. Prema SCORE-u, 110 učesnika (60%) imalo je 10- godišnji rizik od kardiovaskularne smrti  lt 1%, 56 (30%) je imalo 1-5% rizika, dok je kod 19 osoba (10%) identifikovan visok rizik (≥5%). Oko 30% ispitanika svrstano je u različite kategorije rizika na osnovu različitih modela za procenu rizika. Razlike u klasifikaciji na osnovu kardiovaskularnog rizika, koje se dobijaju korišćenjem dva različita algoritma za procenu rizika, mogu se objasniti time što ovi sistemi koriste različite krajnje ishode bolesti i što se razlikuju po uticaju interakcija i uzimanju u obzir upotrebe antihipertenzivnih lekova. Važno je naglasiti da ni FRS ni SCORE nisu prilagođeni našoj populaciji, na osnovu nacionalne stope mortaliteta od KVB.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Comparison of two different methods for cardiovascular risk assessment: Framingham risk score and SCORE system, Poređenje dve metode procene kardiovaskularnog rizika - 'Framingham' rizik skor i 'Score' sistem",
volume = "26",
number = "2",
pages = "94-97",
doi = "10.2478/v10011-007-0012-x"
}

Jovičić, S., Ignjatović, S.,& Majkić-Singh, N.. (2007). Comparison of two different methods for cardiovascular risk assessment: Framingham risk score and SCORE system. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 26(2), 94-97.
https://doi.org/10.2478/v10011-007-0012-x

Jovičić S, Ignjatović S, Majkić-Singh N. Comparison of two different methods for cardiovascular risk assessment: Framingham risk score and SCORE system. in Journal of Medical Biochemistry. 2007;26(2):94-97.
doi:10.2478/v10011-007-0012-x .

Jovičić, Snežana, Ignjatović, Svetlana, Majkić-Singh, Nada, "Comparison of two different methods for cardiovascular risk assessment: Framingham risk score and SCORE system" in Journal of Medical Biochemistry, 26, no. 2 (2007):94-97,
https://doi.org/10.2478/v10011-007-0012-x . .

TY  - JOUR
AU  - Ignjatović, Svetlana
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1009
AB  - The best-validated markers in breast cancer are all tissue based and include estrogen receptors (ER), progesteron receptors (PR), HER-2, urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1). Assay of ER, PR and HER-2 is now mandatory on all newly diagnosed breast cancer patients. The measurement of uPA and PAI-1, although technically and clinically validated, is not yet in widespread clinical use, mainly due to the requirement of a minimum amount of fresh or freshly frozen tissue. Assay of these proteins however, may be used to aid the selection of lymph node-negative breast cancer patients that do not need adjuvant chemotherapy. Although widely used in post-operative surveillance and monitoring therapy in advanced disease, the clinical value of CA 15-3 and other serum markers has not yet been validated by a Level I evidence study. Recent improvements in our understanding of breast cancer biology and a parallel increase in possible treatment options have led to improvements in outcome this very heterogeneous disease. Oncologists still have significant difficulty in tailoring treatment strategies to the molecular characteristics of an individual's disease.
AB  - Najbolje validovani markeri karcinoma dojke pripadaju tkivnim markerima i uključuju receptore za estrogen (ER), receptore za progesteron (PR), HER-2 urokinaza plazminogen aktivator (uPA) i plazminogen aktivator inhibitor 1 (PAI-1). Kod svih novodijagnostikovanih pacijenata sa karcinomom dojke određivanje ER, PR i HER-2 je danas obavezno. Mada je merenje uPA i PAI-1 tehnički validovano, do danas nije klinički rasprostranjeno i to uglavnom zbog zahteva za minimalnom količinom svežeg ili sveže zamrznutog tkiva. Određivanje ovih proteina može da se iskoristi kao pomoć pri selekciji "limfni čvor negativnih" pacijenata s karcinomom dojke kojima nije potrebna adjuvantna hemoterapija. Mada se dosta koristi u postoperativnom praćenju i praćenju terapije u poodmaklom oboljenju, klinička vrednost CA 15-3 i drugih serumskih markera nije još uvek validovana u studijama nivoa dokaza I. Nedavna poboljšanja u razumevanju biologije karcinoma dojke i paralelno povećanje mogućih opcija tretmana treba da vode ka poboljšanju ishoda ove veoma hetrogene bolesti. Onkolozi još uvek imaju teškoće u odabiru specifičnih strategija tretmana prema molekularnim karakteristikama oboljenja svakog pacijenta ponaosob.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Guidelines for the use of tumor markers in breast cancer
T1  - Vodiči za primenu tumorskih markera kod karcinoma dojke
VL  - 26
IS  - 2
SP  - 144
EP  - 156
DO  - 10.2478/v10011-007-0018-4
ER  - 

@article{
author = "Ignjatović, Svetlana",
year = "2007",
abstract = "The best-validated markers in breast cancer are all tissue based and include estrogen receptors (ER), progesteron receptors (PR), HER-2, urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1). Assay of ER, PR and HER-2 is now mandatory on all newly diagnosed breast cancer patients. The measurement of uPA and PAI-1, although technically and clinically validated, is not yet in widespread clinical use, mainly due to the requirement of a minimum amount of fresh or freshly frozen tissue. Assay of these proteins however, may be used to aid the selection of lymph node-negative breast cancer patients that do not need adjuvant chemotherapy. Although widely used in post-operative surveillance and monitoring therapy in advanced disease, the clinical value of CA 15-3 and other serum markers has not yet been validated by a Level I evidence study. Recent improvements in our understanding of breast cancer biology and a parallel increase in possible treatment options have led to improvements in outcome this very heterogeneous disease. Oncologists still have significant difficulty in tailoring treatment strategies to the molecular characteristics of an individual's disease., Najbolje validovani markeri karcinoma dojke pripadaju tkivnim markerima i uključuju receptore za estrogen (ER), receptore za progesteron (PR), HER-2 urokinaza plazminogen aktivator (uPA) i plazminogen aktivator inhibitor 1 (PAI-1). Kod svih novodijagnostikovanih pacijenata sa karcinomom dojke određivanje ER, PR i HER-2 je danas obavezno. Mada je merenje uPA i PAI-1 tehnički validovano, do danas nije klinički rasprostranjeno i to uglavnom zbog zahteva za minimalnom količinom svežeg ili sveže zamrznutog tkiva. Određivanje ovih proteina može da se iskoristi kao pomoć pri selekciji "limfni čvor negativnih" pacijenata s karcinomom dojke kojima nije potrebna adjuvantna hemoterapija. Mada se dosta koristi u postoperativnom praćenju i praćenju terapije u poodmaklom oboljenju, klinička vrednost CA 15-3 i drugih serumskih markera nije još uvek validovana u studijama nivoa dokaza I. Nedavna poboljšanja u razumevanju biologije karcinoma dojke i paralelno povećanje mogućih opcija tretmana treba da vode ka poboljšanju ishoda ove veoma hetrogene bolesti. Onkolozi još uvek imaju teškoće u odabiru specifičnih strategija tretmana prema molekularnim karakteristikama oboljenja svakog pacijenta ponaosob.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Guidelines for the use of tumor markers in breast cancer, Vodiči za primenu tumorskih markera kod karcinoma dojke",
volume = "26",
number = "2",
pages = "144-156",
doi = "10.2478/v10011-007-0018-4"
}

Ignjatović, S.. (2007). Guidelines for the use of tumor markers in breast cancer. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 26(2), 144-156.
https://doi.org/10.2478/v10011-007-0018-4

Ignjatović S. Guidelines for the use of tumor markers in breast cancer. in Journal of Medical Biochemistry. 2007;26(2):144-156.
doi:10.2478/v10011-007-0018-4 .

Ignjatović, Svetlana, "Guidelines for the use of tumor markers in breast cancer" in Journal of Medical Biochemistry, 26, no. 2 (2007):144-156,
https://doi.org/10.2478/v10011-007-0018-4 . .

TY  - JOUR
AU  - Dimitrijević, Olivera
AU  - Đorić-Stojcevski, Blagica
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/713
AB  - Systemic markers of inflammation are considered reliable predictors of future coronary events in patients with acute myocardial infarction (AMI). The aim of this study was to evaluate the prognostic relevance of serial C-reactive protein (CRP) measurements in patients with ST-elevation AMI (STEMI) on one-year outcome. In 31 patients with STEMI, serial measurements of CRP were obtained, and for each patient, the following values were determined: (i) values at admission, up to 12 hours after symptom onset, (ii) maximal values obtained 24-72 hours after symptom onset (early acute values), and (iii) late acute values (96-120 hours after symptom onset). The combined endpoint was any new cardiovascular event, including death. Early and late acute CRP levels were the only parameters found to be significantly higher in patients with an adverse outcome than in patients with a good outcome. A significantly higher rate of endpoint events was found in patients with elevated early (Hazard ratio [HR] 5.54, 95%CI 2.05-25.40; P = 0.007) and late acute CRP (HR 9.01, 95% CI 1.66-19.56; P = 0.005). Multiple logistic regression analysis identified only early acute CRP as an independent predictor of an unfavorable outcome (Odds ratio 8.00, 95%CI 1.15-55.60; P 0.04), after adjustment for established risk factors. CRP level measured 24-72 hours after symptom onset is an independent predictor of one-year outcome in patients with STEML Values obtained later in the setting of STEMI do not add further prognostic information. CRP at admission is not related to long-term prognosis'.
PB  - Int Heart Journal Assoc, Tokyo
T2  - International Heart Journal
T1  - Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome
VL  - 47
IS  - 6
SP  - 833
EP  - 842
DO  - 10.1536/ihj.47.833
ER  - 

@article{
author = "Dimitrijević, Olivera and Đorić-Stojcevski, Blagica and Ignjatović, Svetlana and Majkić-Singh, Nada",
year = "2006",
abstract = "Systemic markers of inflammation are considered reliable predictors of future coronary events in patients with acute myocardial infarction (AMI). The aim of this study was to evaluate the prognostic relevance of serial C-reactive protein (CRP) measurements in patients with ST-elevation AMI (STEMI) on one-year outcome. In 31 patients with STEMI, serial measurements of CRP were obtained, and for each patient, the following values were determined: (i) values at admission, up to 12 hours after symptom onset, (ii) maximal values obtained 24-72 hours after symptom onset (early acute values), and (iii) late acute values (96-120 hours after symptom onset). The combined endpoint was any new cardiovascular event, including death. Early and late acute CRP levels were the only parameters found to be significantly higher in patients with an adverse outcome than in patients with a good outcome. A significantly higher rate of endpoint events was found in patients with elevated early (Hazard ratio [HR] 5.54, 95%CI 2.05-25.40; P = 0.007) and late acute CRP (HR 9.01, 95% CI 1.66-19.56; P = 0.005). Multiple logistic regression analysis identified only early acute CRP as an independent predictor of an unfavorable outcome (Odds ratio 8.00, 95%CI 1.15-55.60; P 0.04), after adjustment for established risk factors. CRP level measured 24-72 hours after symptom onset is an independent predictor of one-year outcome in patients with STEML Values obtained later in the setting of STEMI do not add further prognostic information. CRP at admission is not related to long-term prognosis'.",
publisher = "Int Heart Journal Assoc, Tokyo",
journal = "International Heart Journal",
title = "Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome",
volume = "47",
number = "6",
pages = "833-842",
doi = "10.1536/ihj.47.833"
}

Dimitrijević, O., Đorić-Stojcevski, B., Ignjatović, S.,& Majkić-Singh, N.. (2006). Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. in International Heart Journal
Int Heart Journal Assoc, Tokyo., 47(6), 833-842.
https://doi.org/10.1536/ihj.47.833

Dimitrijević O, Đorić-Stojcevski B, Ignjatović S, Majkić-Singh N. Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. in International Heart Journal. 2006;47(6):833-842.
doi:10.1536/ihj.47.833 .

Dimitrijević, Olivera, Đorić-Stojcevski, Blagica, Ignjatović, Svetlana, Majkić-Singh, Nada, "Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome" in International Heart Journal, 47, no. 6 (2006):833-842,
https://doi.org/10.1536/ihj.47.833 . .

TY  - JOUR
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/881
AB  - Evidence-based medicine (EBM) combines individual clinical expertise with the best available clinical evidence from systematic research in making decisions about the care of individual patients. Clinical expertise is the proficiency and judgment that individual clinicians acquire through knowledge, clinical experience, and practice. Clinical evidence comes from patient-centered clinical research which investigates the accuracy and precision of diagnostic tests and biomarkers, the efficacy and safety of therapeutic regimes, and the reliability of prognostic indicators. The powerful combination of clinical expertise and documented evidence results in safer, more efficacious and accurate care of the patient. Evidence-based guidelines are commonly used tools for supporting medical decisions. Formulating evidence-based recommendations has become a leading principle in guideline development. In laboratory medicine, guidelines provide recommendations on the use of a wide range of tests in detecting or predicting a target condition, for staging and monitoring a disease, and for decisions to initiate, modify, or terminate treatments. Systematic, standardized, and explicit methodology, adapted to laboratory medicine, should be followed when developing recommendations involving the use of laboratory tests and biomarkers. There are many opportunities for the application and evaluation of laboratory tests in good clinical trials. There are even greater opportunities for correlating various laboratory procedures with the clinical findings, outcomes and diagnoses, and using the stored samples collected for those studies. In this era of evidence-based medicine, clinicians and other decision-makers turn to the scientific literature for high-quality evidence about the usefulness, precision, and accuracy of diagnostic tests. Such evidence is needed more than ever because the list of diagnostic tests is growing exponentially, and even more biomarkers, proteomics, and applications of gene expression profiling will be added in the years to come.
AB  - Medicina zasnovana na dokazima (EBM) pri donošenju odluka o nezi pacijenata kombinuje individualnu kliničku veštinu sa najboljim raspoloživim kliničkim dokazima iz sistematičnih istraživanja. Klinička veština odlikuje se tačnošću u proceni i stiče se učenjem, kliničkim iskustvom i praksom. Klinički dokazi dobijaju se iz kliničkih istraživanja koja su usmerena na pacijenta, a koja ispituju tačnost i preciznost dijagnostičkih testova i biomarkera, efikasnost i sigurnost terapeutskih postupaka i pouzdanost prognostičkih indikatora. Kombinacija kliničke veštine i dokumentovanih dokaza omogućava sigurniju, efikasniju i pouzdaniju negu pacijenta. Vodiči zasnovani na dokazima najčešće se koriste kao dodatne alatke pri donošenju medicinskih odluka. Formulisanje preporuka zasnovanih na dokazima predstavlja vodeći princip u pripremi vodiči. U razvoju preporuka koje uključuju laboratorijske testove i biomarkere treba primeniti sistematsku i standardizovanu metodologiju koja je prilagođena laboratorijskoj medicini. Postoji veliki broj mogućnosti za primenu i evaluaciju laboratorijskih testova u dobrim kliničkim ispitivanjima. Još su veće mogućnosti za uspostavljanje korelacija između različitih laboratorijskih postupaka i kliničkih nalaza, ishoda i dijagnoza, kao i za korišćenje uzoraka koji su skladišteni za ova ispitivanja. Era medicine zasnovane na dokazima zahteva od eksperata koji donose medicinske odluke proučavanje naučne literature kako bi se obezbedio visok kvalitet dokaza o korisnosti i tačnosti dijagnostičkih testova. Ovakva vrsta dokaza potrebnija je više nego ikad zato što lista dijagnostičkih testova raste eksponencijalno i u godinama koje dolaze na nju će biti dodato još više biomarkera, proteomike aplikacija profiliranja ekspresije gena.
PB  - Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd
T2  - Jugoslovenska medicinska biohemija
T1  - Biomarkers of diseases: An evidence-based approach
T1  - Biomarkeri oboljenja - pristup zasnovan na dokazima
VL  - 25
IS  - 3
SP  - 227
EP  - 233
DO  - 10.2298/JMB0603227I
ER  - 

@article{
author = "Ignjatović, Svetlana and Majkić-Singh, Nada",
year = "2006",
abstract = "Evidence-based medicine (EBM) combines individual clinical expertise with the best available clinical evidence from systematic research in making decisions about the care of individual patients. Clinical expertise is the proficiency and judgment that individual clinicians acquire through knowledge, clinical experience, and practice. Clinical evidence comes from patient-centered clinical research which investigates the accuracy and precision of diagnostic tests and biomarkers, the efficacy and safety of therapeutic regimes, and the reliability of prognostic indicators. The powerful combination of clinical expertise and documented evidence results in safer, more efficacious and accurate care of the patient. Evidence-based guidelines are commonly used tools for supporting medical decisions. Formulating evidence-based recommendations has become a leading principle in guideline development. In laboratory medicine, guidelines provide recommendations on the use of a wide range of tests in detecting or predicting a target condition, for staging and monitoring a disease, and for decisions to initiate, modify, or terminate treatments. Systematic, standardized, and explicit methodology, adapted to laboratory medicine, should be followed when developing recommendations involving the use of laboratory tests and biomarkers. There are many opportunities for the application and evaluation of laboratory tests in good clinical trials. There are even greater opportunities for correlating various laboratory procedures with the clinical findings, outcomes and diagnoses, and using the stored samples collected for those studies. In this era of evidence-based medicine, clinicians and other decision-makers turn to the scientific literature for high-quality evidence about the usefulness, precision, and accuracy of diagnostic tests. Such evidence is needed more than ever because the list of diagnostic tests is growing exponentially, and even more biomarkers, proteomics, and applications of gene expression profiling will be added in the years to come., Medicina zasnovana na dokazima (EBM) pri donošenju odluka o nezi pacijenata kombinuje individualnu kliničku veštinu sa najboljim raspoloživim kliničkim dokazima iz sistematičnih istraživanja. Klinička veština odlikuje se tačnošću u proceni i stiče se učenjem, kliničkim iskustvom i praksom. Klinički dokazi dobijaju se iz kliničkih istraživanja koja su usmerena na pacijenta, a koja ispituju tačnost i preciznost dijagnostičkih testova i biomarkera, efikasnost i sigurnost terapeutskih postupaka i pouzdanost prognostičkih indikatora. Kombinacija kliničke veštine i dokumentovanih dokaza omogućava sigurniju, efikasniju i pouzdaniju negu pacijenta. Vodiči zasnovani na dokazima najčešće se koriste kao dodatne alatke pri donošenju medicinskih odluka. Formulisanje preporuka zasnovanih na dokazima predstavlja vodeći princip u pripremi vodiči. U razvoju preporuka koje uključuju laboratorijske testove i biomarkere treba primeniti sistematsku i standardizovanu metodologiju koja je prilagođena laboratorijskoj medicini. Postoji veliki broj mogućnosti za primenu i evaluaciju laboratorijskih testova u dobrim kliničkim ispitivanjima. Još su veće mogućnosti za uspostavljanje korelacija između različitih laboratorijskih postupaka i kliničkih nalaza, ishoda i dijagnoza, kao i za korišćenje uzoraka koji su skladišteni za ova ispitivanja. Era medicine zasnovane na dokazima zahteva od eksperata koji donose medicinske odluke proučavanje naučne literature kako bi se obezbedio visok kvalitet dokaza o korisnosti i tačnosti dijagnostičkih testova. Ovakva vrsta dokaza potrebnija je više nego ikad zato što lista dijagnostičkih testova raste eksponencijalno i u godinama koje dolaze na nju će biti dodato još više biomarkera, proteomike aplikacija profiliranja ekspresije gena.",
publisher = "Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd",
journal = "Jugoslovenska medicinska biohemija",
title = "Biomarkers of diseases: An evidence-based approach, Biomarkeri oboljenja - pristup zasnovan na dokazima",
volume = "25",
number = "3",
pages = "227-233",
doi = "10.2298/JMB0603227I"
}

Ignjatović, S.,& Majkić-Singh, N.. (2006). Biomarkers of diseases: An evidence-based approach. in Jugoslovenska medicinska biohemija
Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd., 25(3), 227-233.
https://doi.org/10.2298/JMB0603227I

Ignjatović S, Majkić-Singh N. Biomarkers of diseases: An evidence-based approach. in Jugoslovenska medicinska biohemija. 2006;25(3):227-233.
doi:10.2298/JMB0603227I .

Ignjatović, Svetlana, Majkić-Singh, Nada, "Biomarkers of diseases: An evidence-based approach" in Jugoslovenska medicinska biohemija, 25, no. 3 (2006):227-233,
https://doi.org/10.2298/JMB0603227I . .

TY  - JOUR
AU  - Ignjatović, Svetlana
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/880
AB  - As with all diagnostic tests, tumor markers are surrogate indicators that can be used clinically to increase or decrease the clinician’s suspicion that a future clinically important event will or will not happen, and/or that a specific treatment will reduce that risk. To determine the clinical utility of tumor markers, one of several potential uses must be designated, including risk assessment, screening, differential diagnosis, prognosis, and monitoring clinical course. Within these uses, only tumor markers for which the results effect a change that results in a more favorable clinical outcome (overall survival, disease free survival, quality of life, or decreased cost) are recommended for routine clinical use. Introduction of tumor markers into routine clinical practice has been poorly controlled, with few criteria or guidelines as to how such markers should be used. However, unlike the objective criteria established to evaluate new therapeutic agents, few guidelines have been established to determine if and/or when use of a tumor markers should become standard. Dr. Daniel Hayes of the University of Michigan, Ann Arbor, Michigan, United States and coworkers have proposed that it is appropriate to establish similar criteria for evaluation of tumor markers and to standardize the tumor marker information for clinical utility. The proposed an evidence-based system is called the Tumor Marker Utility Grading System or TMUGS. Acceptance of a tumor marker for clinical utility requires careful and thoughtful study design so that the results are meaningful in the clinical setting.
AB  - Kao svi dijagnostički testovi, tumorski markeri su surogat indikatori koji klinički mogu da se upotrebe za povećanje ili smanjenje sumnje lekara o tome da se neki važan događaj u budućnosti može da dogode ili ne dogode, kao i/ili da će se specifičnim tretmanom smanjiti rizik. Da bi se odredila klinička korisnost tumorskih markera neophodno je da rezultati njihovog određivanja precizno odgovaraju situaciji rizika, "skrininga", dijagnoze, prognoze, predviđanja i praćenja kliničkog toka. Za rutinsku kliničku praksu preporučuju se oni tumorski markeri koji mogu da pomognu pri donošenju pouzdanih kliničkih odluka koje će rezultirati u poboljšanju u jednom od četiri klinička ishoda: obuhvatno preživljavanje, preživljavanje bez bolesti, kvalitet života ili koštanje lečenja. Uvođenje tumorskih markera u rutinsku kliničku praksu je loše kontrolisano uz primenu nekoliko kriterijuma ili vodiča za njihovo korišćenje. Suprotno činjenici da postoje objektivni kriterijumi za evaluaciju terapeutskih agenasa, samo nekoliko vodiča za primenu tumorskih markera je postalo standard. Dr. Daniel Hayes sa "Ann Arbor" Univerziteta u Mičigenu, SAD i saradnici su preporučili uspostavljanje sličnih kriterijuma u evaluaciji tumorskih markera i standardizaciju njihove kliničke korisnosti. Preporučeni sistem zasnovan na dokazima je nazvan Tumor Marker Utility Grading System ili TMUGS. Prihvatanje tumorskih markera u kliničkoj praksi zahteva temeljan i smisleni dizajn studije tako da rezultati budu značajni u kliničkoj situaciji.
PB  - Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd
T2  - Jugoslovenska medicinska biohemija
T1  - Clinical utility of tumor markers
T1  - Klinička korisnost tumorskih markera
VL  - 25
IS  - 2
SP  - 119
EP  - 125
DO  - 10.2298/JMB0602119I
ER  - 

@article{
author = "Ignjatović, Svetlana",
year = "2006",
abstract = "As with all diagnostic tests, tumor markers are surrogate indicators that can be used clinically to increase or decrease the clinician’s suspicion that a future clinically important event will or will not happen, and/or that a specific treatment will reduce that risk. To determine the clinical utility of tumor markers, one of several potential uses must be designated, including risk assessment, screening, differential diagnosis, prognosis, and monitoring clinical course. Within these uses, only tumor markers for which the results effect a change that results in a more favorable clinical outcome (overall survival, disease free survival, quality of life, or decreased cost) are recommended for routine clinical use. Introduction of tumor markers into routine clinical practice has been poorly controlled, with few criteria or guidelines as to how such markers should be used. However, unlike the objective criteria established to evaluate new therapeutic agents, few guidelines have been established to determine if and/or when use of a tumor markers should become standard. Dr. Daniel Hayes of the University of Michigan, Ann Arbor, Michigan, United States and coworkers have proposed that it is appropriate to establish similar criteria for evaluation of tumor markers and to standardize the tumor marker information for clinical utility. The proposed an evidence-based system is called the Tumor Marker Utility Grading System or TMUGS. Acceptance of a tumor marker for clinical utility requires careful and thoughtful study design so that the results are meaningful in the clinical setting., Kao svi dijagnostički testovi, tumorski markeri su surogat indikatori koji klinički mogu da se upotrebe za povećanje ili smanjenje sumnje lekara o tome da se neki važan događaj u budućnosti može da dogode ili ne dogode, kao i/ili da će se specifičnim tretmanom smanjiti rizik. Da bi se odredila klinička korisnost tumorskih markera neophodno je da rezultati njihovog određivanja precizno odgovaraju situaciji rizika, "skrininga", dijagnoze, prognoze, predviđanja i praćenja kliničkog toka. Za rutinsku kliničku praksu preporučuju se oni tumorski markeri koji mogu da pomognu pri donošenju pouzdanih kliničkih odluka koje će rezultirati u poboljšanju u jednom od četiri klinička ishoda: obuhvatno preživljavanje, preživljavanje bez bolesti, kvalitet života ili koštanje lečenja. Uvođenje tumorskih markera u rutinsku kliničku praksu je loše kontrolisano uz primenu nekoliko kriterijuma ili vodiča za njihovo korišćenje. Suprotno činjenici da postoje objektivni kriterijumi za evaluaciju terapeutskih agenasa, samo nekoliko vodiča za primenu tumorskih markera je postalo standard. Dr. Daniel Hayes sa "Ann Arbor" Univerziteta u Mičigenu, SAD i saradnici su preporučili uspostavljanje sličnih kriterijuma u evaluaciji tumorskih markera i standardizaciju njihove kliničke korisnosti. Preporučeni sistem zasnovan na dokazima je nazvan Tumor Marker Utility Grading System ili TMUGS. Prihvatanje tumorskih markera u kliničkoj praksi zahteva temeljan i smisleni dizajn studije tako da rezultati budu značajni u kliničkoj situaciji.",
publisher = "Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd",
journal = "Jugoslovenska medicinska biohemija",
title = "Clinical utility of tumor markers, Klinička korisnost tumorskih markera",
volume = "25",
number = "2",
pages = "119-125",
doi = "10.2298/JMB0602119I"
}

Ignjatović, S.. (2006). Clinical utility of tumor markers. in Jugoslovenska medicinska biohemija
Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd., 25(2), 119-125.
https://doi.org/10.2298/JMB0602119I

Ignjatović S. Clinical utility of tumor markers. in Jugoslovenska medicinska biohemija. 2006;25(2):119-125.
doi:10.2298/JMB0602119I .

Ignjatović, Svetlana, "Clinical utility of tumor markers" in Jugoslovenska medicinska biohemija, 25, no. 2 (2006):119-125,
https://doi.org/10.2298/JMB0602119I . .